{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:46:07Z","timestamp":1794962767247,"version":"4.9.1"},"reference-count":378,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Therapeutic cancer vaccines aim to expand and activate antigen-specific T cells for the targeted elimination of cancer cells. While early clinical trials faced challenges due to suboptimal antigen-specific T-cell activation, recent advancements in antigen discovery and vaccine platform engineering have revitalized the field. This review provides a comprehensive overview of key tumor antigens, including tumor-associated antigens, viral oncoprotein antigens, neoantigens, and cryptic antigens, with a focus on their immunogenicity and therapeutic potential. Advances in our understanding of traditional cancer vaccination targets, in conjunction with the timely identification of novel antigen epitopes, have facilitated the strategic selection of vaccination targets. We also discuss the evolution of cancer vaccine platforms\u2014spanning peptide-based formulations to advanced mRNA vectors\u2014emphasizing innovative strategies to optimize antigen delivery efficiency and adjuvant effects. Efficient antigen delivery and adjuvant selection overcome immune tolerance and tumor-induced immunosuppression. Furthermore, we examine recent clinical trial data and emerging combination approaches that integrate cancer vaccines with other immunotherapies to increase efficacy. While significant progress has been made, challenges remain in improving vaccine-induced T-cell responses, overcoming immune suppression, and translating these advances into effective clinical interventions. Addressing these hurdles will be critical for realizing the full potential of cancer vaccines in immunotherapy.<\/jats:p>","DOI":"10.1038\/s41423-025-01316-4","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:44:38Z","timestamp":1752137078000},"page":"840-868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Eliciting antitumor immunity via therapeutic cancer vaccines"],"prefix":"10.1038","volume":"22","author":[{"given":"Kun","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-6617","authenticated-orcid":false,"given":"Yang-Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"1316_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol: Mechanisms Dis. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol: Mechanisms Dis"},{"key":"1316_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002\u201314.","journal-title":"Lancet"},{"key":"1316_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol. 2022;40:45\u201374.","journal-title":"Annu Rev Immunol"},{"key":"1316_CR4","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42:1825\u201363.","journal-title":"Cancer Cell"},{"key":"1316_CR5","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: building a bridge over troubled waters. Cell. 2022;185:2770\u201388.","journal-title":"Cell"},{"key":"1316_CR6","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","volume":"3","author":"MJ Lin","year":"2022","unstructured":"Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, et al. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022;3:911\u201326.","journal-title":"Nat Cancer"},{"key":"1316_CR7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909\u201315.","journal-title":"Nat Med"},{"key":"1316_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"1316_CR9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329\u201360.","journal-title":"Annu Rev Immunol"},{"key":"1316_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang F, Schr\u00f6rs B, L\u00f6wer M, T\u00fcreci \u00d6, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov. 2022;21:261\u201382.","journal-title":"Nat Rev Drug Discov"},{"key":"1316_CR11","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1172\/JCI80009","volume":"125","author":"CJ Melief","year":"2015","unstructured":"Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125:3401\u201312.","journal-title":"J Clin Invest"},{"key":"1316_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","volume":"135","author":"C Gutierrez","year":"2011","unstructured":"Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135:55\u201362.","journal-title":"Arch Pathol Lab Med"},{"key":"1316_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22:101\u201326.","journal-title":"Nat Rev Drug Discov"},{"key":"1316_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1172\/JCI11752","volume":"107","author":"KL Knutson","year":"2001","unstructured":"Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2\/neu helper peptide vaccine generates HER-2\/neu CD8 T-cell immunity in cancer patients. J Clin Invest. 2001;107:477\u201384.","journal-title":"J Clin Invest"},{"key":"1316_CR15","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","volume":"364","author":"DJ Schwartzentruber","year":"2011","unstructured":"Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119\u201327.","journal-title":"N Engl J Med"},{"key":"1316_CR16","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1084\/jem.179.3.1005","volume":"179","author":"AB Bakker","year":"1994","unstructured":"Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179:1005\u20139.","journal-title":"J Exp Med"},{"key":"1316_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"1316_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1084\/jem.20030590","volume":"198","author":"WW Overwijk","year":"2003","unstructured":"Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8\u2009+\u2009T cells. J Exp Med. 2003;198:569\u201380.","journal-title":"J Exp Med"},{"key":"1316_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.canlet.2005.05.021","volume":"236","author":"AC Cunha","year":"2006","unstructured":"Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and nonprostatic tissues. Cancer Lett. 2006;236:229\u201338.","journal-title":"Cancer Lett"},{"key":"1316_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"1316_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3892\/or.2020.7847","volume":"45","author":"M Noguchi","year":"2021","unstructured":"Noguchi M, Fujimoto K, Arai G, Uemura H, Hashine K, Matsumoto H, et al. A randomized phase III trial of personalized peptide vaccination for castration\u2011resistant prostate cancer progressing after docetaxel. Oncol Rep. 2021;45:159\u201368.","journal-title":"Oncol Rep"},{"key":"1316_CR22","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1158\/1078-0432.CCR-17-2709","volume":"24","author":"NR Hardwick","year":"2018","unstructured":"Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, et al. p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clin Cancer Res. 2018;24:1315\u201325.","journal-title":"Clin Cancer Res"},{"key":"1316_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12094-018-1932-2","volume":"21","author":"V Chung","year":"2019","unstructured":"Chung V, Kos FJ, Hardwick N, Yuan Y, Chao J, Li D, et al. Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. Clin Transl Oncol. 2019;21:363\u201372.","journal-title":"Clin Transl Oncol"},{"key":"1316_CR24","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1158\/1078-0432.CCR-22-3168","volume":"29","author":"RE Schoen","year":"2023","unstructured":"Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenberg D, Hur C, et al. Randomized, double-blind, placebo-controlled trial of MUC1 peptide vaccine for prevention of recurrent colorectal adenoma. Clin Cancer Res. 2023;29:1678\u201388.","journal-title":"Clin Cancer Res"},{"key":"1316_CR25","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","volume":"27","author":"JW Kjeldsen","year":"2021","unstructured":"Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, et al. A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med. 2021;27:2212\u201323.","journal-title":"Nat Med"},{"key":"1316_CR26","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00262-016-1890-x","volume":"65","author":"RA Fenstermaker","year":"2016","unstructured":"Fenstermaker RA, Ciesielski MJ, Qiu J, Yang N, Frank CL, Lee KP, et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 2016;65:1339\u201352.","journal-title":"Cancer Immunol Immunother"},{"key":"1316_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/jjco\/hyp194","volume":"40","author":"H Sugiyama","year":"2010","unstructured":"Sugiyama H. WT1 (Wilms\u2019 Tumor Gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010;40:377\u201387.","journal-title":"Jpn J Clin Oncol"},{"key":"1316_CR28","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323\u201337.","journal-title":"Clin Cancer Res"},{"key":"1316_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","volume":"2","author":"PG Maslak","year":"2018","unstructured":"Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2:224\u201334.","journal-title":"Blood Adv"},{"key":"1316_CR30","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","volume":"9","author":"R Thomas","year":"2018","unstructured":"Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018;9:947.","journal-title":"Front Immunol"},{"key":"1316_CR31","doi-asserted-by":"publisher","first-page":"E10702","DOI":"10.1073\/pnas.1810653115","volume":"115","author":"MT Bethune","year":"2018","unstructured":"Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, et al. Isolation and characterization of NY-ESO-1\u2013specific T-cell receptors restricted on various MHC molecules. Proc Natl Acad Sci. 2018;115:E10702\u2013E10711.","journal-title":"Proc Natl Acad Sci"},{"key":"1316_CR32","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1073\/pnas.061507398","volume":"98","author":"G Zeng","year":"2001","unstructured":"Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(\u2009+\u2009) T-cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA. 2001;98:3964\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1316_CR33","doi-asserted-by":"publisher","first-page":"12837","DOI":"10.1073\/pnas.0703342104","volume":"104","author":"K Odunsi","year":"2007","unstructured":"Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, et al. Vaccination with an NY-ESO-1 peptide of HLA class I\/II specificities induces integrated humoral and T-cell responses in ovarian cancer. Proc Natl Acad Sci USA. 2007;104:12837\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1316_CR34","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1158\/1078-0432.CCR-12-2189","volume":"18","author":"P Sabbatini","year":"2012","unstructured":"Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012;18:6497\u2013508.","journal-title":"Clin Cancer Res"},{"key":"1316_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00262-017-2085-9","volume":"67","author":"O Gasser","year":"2018","unstructured":"Gasser O, Sharples KJ, Barrow C, Williams GM, Bauer E, Wood CE, et al. A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and \u03b1-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. Cancer Immunol Immunother. 2018;67:285\u201398.","journal-title":"Cancer Immunol Immunother"},{"key":"1316_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019\u201327.","journal-title":"Clin Cancer Res"},{"key":"1316_CR37","doi-asserted-by":"crossref","unstructured":"Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585:107\u201312.","DOI":"10.1038\/s41586-020-2537-9"},{"key":"1316_CR38","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2217\/imt.15.29","volume":"7","author":"A Esfandiary","year":"2015","unstructured":"Esfandiary A, Ghafouri-Fard S. MAGE-A3: an immunogenic target used in clinical practice. Immunotherapy. 2015;7:683\u2013704.","journal-title":"Immunotherapy"},{"key":"1316_CR39","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1200\/JCO.2012.43.7103","volume":"31","author":"J Vansteenkiste","year":"2013","unstructured":"Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small cell lung cancer: phase II randomized study results. J Clin Oncol. 2013;31:2396\u2013403.","journal-title":"J Clin Oncol"},{"key":"1316_CR40","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","volume":"19","author":"B Dreno","year":"2018","unstructured":"Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, et al. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:916\u201329.","journal-title":"Lancet Oncol"},{"key":"1316_CR41","unstructured":"Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, Milhem M, Markovic SN, et al. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. J Immunother Cancer. 2021;9:e003272."},{"key":"1316_CR42","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/nrc2961","volume":"10","author":"PS Moore","year":"2010","unstructured":"Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumor virology. Nat Rev Cancer. 2010;10:878\u201389.","journal-title":"Nat Rev Cancer"},{"key":"1316_CR43","doi-asserted-by":"publisher","first-page":"29311","DOI":"10.18632\/oncotarget.4906","volume":"6","author":"YP Chen","year":"2015","unstructured":"Chen YP, Zhang WN, Chen L, Tang LL, Mao YP, Li WF, et al. Effect of latent membrane protein 1 expression on overall survival in Epstein\u2012Barr virus-associated cancers: a literature-based meta-analysis. Oncotarget. 2015;6:29311\u201323.","journal-title":"Oncotarget"},{"key":"1316_CR44","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein\u2012Barr virus latent membrane proteins. J Clin Oncol. 2014;32:798\u2013808.","journal-title":"J Clin Oncol"},{"key":"1316_CR45","doi-asserted-by":"publisher","first-page":"2302116","DOI":"10.1002\/advs.202302116","volume":"10","author":"GX Zhao","year":"2023","unstructured":"Zhao GX, Bu GL, Liu GF, Kong XW, Sun C, Li ZQ, et al. mRNA-based vaccines targeting the T-cell epitope-rich domain of Epstein Barr virus latent proteins elicit robust anti-tumor immunity in mice. Adv Science. 2023;10:2302116.","journal-title":"Adv Science"},{"key":"1316_CR46","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","volume":"20","author":"GS Taylor","year":"2014","unstructured":"Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, et al. A recombinant modified vaccinia ankara vaccine encoding Epstein\u2012Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res. 2014;20:5009\u201322.","journal-title":"Clin Cancer Res"},{"key":"1316_CR47","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fmicb.2019.03116","volume":"10","author":"A Pal","year":"2020","unstructured":"Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol. 2020;10:3116.","journal-title":"Front Microbiol"},{"key":"1316_CR48","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","volume":"19","author":"M Lechner","year":"2022","unstructured":"Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nature Reviews Clin Oncol. 2022;19:306\u201327.","journal-title":"Nature Reviews Clin Oncol"},{"key":"1316_CR49","doi-asserted-by":"publisher","first-page":"eabn3464","DOI":"10.1126\/scitranslmed.abn3464","volume":"15","author":"J Ramos da Silva","year":"2023","unstructured":"Ramos da Silva J, Bitencourt Rodrigues K, Formoso Pelegrin G, Silva Sales N, Muramatsu H, de Oliveira Silva M, et al. Single immunizations of self-amplifying or nonreplicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med. 2023;15:eabn3464.","journal-title":"Sci Transl Med"},{"key":"1316_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52104-z","volume":"15","author":"J He","year":"2024","unstructured":"He J, Wang C, Fang X, Li J, Shen X, Zhang J, et al. Tuning the fluidity and protein corona of ultrasound-responsive liposomal nanovaccines to program T-cell immunity in mice. Nat Commun. 2024;15:8121.","journal-title":"Nat Commun"},{"key":"1316_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","volume":"5","author":"E Massarelli","year":"2019","unstructured":"Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16\u2013related cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5:67\u201373.","journal-title":"JAMA Oncol"},{"key":"1316_CR52","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","volume":"386","author":"CL Trimble","year":"2015","unstructured":"Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomized, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386:2078\u201388.","journal-title":"Lancet"},{"key":"1316_CR53","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ygyno.2019.03.250","volume":"153","author":"DM Harper","year":"2019","unstructured":"Harper DM, Nieminen P, Donders G, Einstein MH, Garcia F, Huh WK, et al. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up. Gynecol Oncol. 2019;153:521\u20139.","journal-title":"Gynecol Oncol"},{"key":"1316_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1055-6","volume":"18","author":"M Peng","year":"2019","unstructured":"Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18:128.","journal-title":"Mol Cancer"},{"key":"1316_CR55","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18:215\u201329.","journal-title":"Nat Rev Clin Oncol"},{"key":"1316_CR56","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ott PA, Wu CJ. Toward personalized, tumor specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18:168\u201382.","journal-title":"Nat Rev Immunol"},{"key":"1316_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69\u201374.","journal-title":"Science"},{"key":"1316_CR58","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","volume":"615","author":"C Puig-Saus","year":"2023","unstructured":"Puig-Saus C, Sennino B, Peng S, Wang CL, Pan Z, Yuen B, et al. Neoantigen-targeted CD8\u2009+\u2009T-cell responses with PD-1 blockade therapy. Nature. 2023;615:697\u2013704.","journal-title":"Nature"},{"key":"1316_CR59","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1126\/science.abl5447","volume":"375","author":"FJ Lowery","year":"2022","unstructured":"Lowery FJ, Krishna S, Yossef R, Parikh NB, Chatani PD, Zacharakis N, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science. 2022;375:877\u201384.","journal-title":"Science"},{"key":"1316_CR60","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ccell.2022.03.005","volume":"40","author":"C Zheng","year":"2022","unstructured":"Zheng C, Fass JN, Shih YP, Gunderson AJ, Sanjuan Silva N, Huang H, et al. Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. Cancer Cell. 2022;40:410\u2013423.e7.","journal-title":"Cancer Cell"},{"key":"1316_CR61","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nm.3773","volume":"21","author":"C Linnemann","year":"2015","unstructured":"Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4\u2009+\u2009T cells in human melanoma. Nat Med. 2015;21:81\u201385.","journal-title":"Nat Med"},{"key":"1316_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41571-024-00969-w","volume":"22","author":"M Zhao","year":"2024","unstructured":"Zhao M, Schoenfeld JD, Egloff AM, Hanna GJ, Haddad RI, Adkins DR, et al. T-cell dynamics with neoadjuvant immunotherapy in head and neck cancer. Nat Rev Clin Oncol. 2024;22:83\u201394.","journal-title":"Nat Rev Clin Oncol"},{"key":"1316_CR63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","volume":"19","author":"CC Smith","year":"2019","unstructured":"Smith CC, Selitsky SR, Chai S, Armistead PM, Vincent BG, Serody JS. Alternative tumor-specific antigens. Nat Rev Cancer. 2019;19:465\u201378.","journal-title":"Nat Rev Cancer"},{"key":"1316_CR64","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124\u20138.","journal-title":"Science"},{"key":"1316_CR65","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","volume":"25","author":"TE Keenan","year":"2019","unstructured":"Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nat Med. 2019;25:389\u2013402.","journal-title":"Nat Med"},{"key":"1316_CR66","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6:386 p.","journal-title":"Signal Transduct Target Ther"},{"key":"1316_CR67","first-page":"645","volume":"18","author":"CJ Pirozzi","year":"2021","unstructured":"Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nature Reviews. Clin Oncol. 2021;18:645\u201361.","journal-title":"Clin Oncol"},{"key":"1316_CR68","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.aad1253","volume":"350","author":"E Tran","year":"2015","unstructured":"Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350:1387\u201390.","journal-title":"Science"},{"key":"1316_CR69","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, et al. Insertion-and-deletion-derived tumor-specific neoantigens and the immunogenic phenotype: a pancancer analysis. Lancet Oncol. 2017;18:1009\u201321.","journal-title":"Lancet Oncol"},{"key":"1316_CR70","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.cell.2020.11.004","volume":"183","author":"V Roudko","year":"2020","unstructured":"Roudko V, Bozkus CC, Orfanelli T, McClain CB, Carr C, O'Donnell T, et al. Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell. 2020;183:1634\u20131649.e17.","journal-title":"Cell"},{"key":"1316_CR71","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.celrep.2018.03.050","volume":"23","author":"Q Gao","year":"2018","unstructured":"Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 2018;23:227\u2013238.e3.","journal-title":"Cell Rep"},{"key":"1316_CR72","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/315550a0","volume":"315","author":"E Shtivelman","year":"1985","unstructured":"Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature. 1985;315:550\u20134.","journal-title":"Nature"},{"key":"1316_CR73","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/nbt.4239","volume":"36","author":"AC Smart","year":"2018","unstructured":"Smart AC, Margolis CA, Pimentel H, He MX, Miao D, Adeegbe D, et al. Intron retention is a source of neoepitopes in cancer. Nat Biotechnol. 2018;36:1056\u20138.","journal-title":"Nat Biotechnol"},{"key":"1316_CR74","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","volume":"34","author":"A Kahles","year":"2018","unstructured":"Kahles A, Lehmann KV, Toussaint NC, H\u00fcser M, Stark SG, Sachsenberg T, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell. 2018;34:211\u2013224.e6.","journal-title":"Cancer Cell"},{"key":"1316_CR75","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.immuni.2021.03.001","volume":"54","author":"G Ehx","year":"2021","unstructured":"Ehx G, Larouche JD, Durette C, Laverdure JP, Hesnard L, Vincent K, et al. Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Immunity. 2021;54:737\u2013752.e10.","journal-title":"Immunity"},{"key":"1316_CR76","doi-asserted-by":"crossref","unstructured":"Laumont CM, Vincent K, Hesnard L, Audemard \u00c9, Bonneil \u00c9, Laverdure JP, et al. Noncoding regions are the main source of targetable tumor-specific antigens. Sci Transl Med. 2018;10:eaau5516.","DOI":"10.1126\/scitranslmed.aau5516"},{"key":"1316_CR77","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41587-021-01038-8","volume":"40","author":"C Chong","year":"2022","unstructured":"Chong C, Coukos G, Bassani-Sternberg M. Identification of tumor antigens with immunopeptidomics. Nat Biotechnol. 2022;40:175\u201388.","journal-title":"Nat Biotechnol"},{"key":"1316_CR78","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41587-022-01464-2","volume":"41","author":"A Kacen","year":"2023","unstructured":"Kacen A, Javitt A, Kramer MP, Morgenstern D, Tsaban T, Shmueli MD, et al. Posttranslational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors. Nat Biotechnol. 2023;41:239\u201351.","journal-title":"Nat Biotechnol"},{"key":"1316_CR79","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/annonc\/mdy413","volume":"29","author":"AS Attermann","year":"2018","unstructured":"Attermann AS, Bjerregaard AM, Saini SK, Gr\u00f8nb\u00e6k K, Hadrup SR. Human endogenous retroviruses and their implication for immunotherapeutics of cancer. Ann Oncol. 2018;29:2183\u201391.","journal-title":"Ann Oncol"},{"key":"1316_CR80","doi-asserted-by":"publisher","unstructured":"Apavaloaei A, Zhao Q, Hesnard L, Cahuzac M, Durette C, Larouche J-D, et al. Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer. Nat Cancer. 2025. https:\/\/doi.org\/10.1038\/s43018-025-00979-2.","DOI":"10.1038\/s43018-025-00979-2"},{"key":"1316_CR81","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41587-022-01247-9","volume":"40","author":"D Weber","year":"2022","unstructured":"Weber D, Ibn-Salem J, Sorn P, Suchan M, Holtstr\u00e4ter C, Lahrmann U, et al. Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens. Nat Biotechnol. 2022;40:1276\u201384.","journal-title":"Nat Biotechnol"},{"key":"1316_CR82","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-18-1494","volume":"9","author":"MR Parkhurst","year":"2019","unstructured":"Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov. 2019;9:1022\u201335.","journal-title":"Cancer Discov"},{"key":"1316_CR83","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1172\/JCI80008","volume":"125","author":"RD Schreiber","year":"2015","unstructured":"Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125:3413\u201321.","journal-title":"J Clin Invest"},{"key":"1316_CR84","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213\u20139.","journal-title":"Nat Biotechnol"},{"key":"1316_CR85","doi-asserted-by":"publisher","first-page":"15.7.1","DOI":"10.1002\/0471250953.bi1507s52","volume":"52","author":"KM Raine","year":"2015","unstructured":"Raine KM, Hinton J, Butler AP, Teague JW, Davies H, Tarpey P, et al. cgpPindel: identifying somatically acquired insertion and deletion events from paired end sequencing. Curr Protoc Bioinforma. 2015;52:15.7.1\u201315.7.12.","journal-title":"Curr Protoc Bioinforma"},{"key":"1316_CR86","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/nbt.3027","volume":"32","author":"V Moncunill","year":"2014","unstructured":"Moncunill V, Gonzalez S, Be\u00e0 S, Andrieux LO, Salaverria I, Royo C, et al. Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads. Nat Biotechnol. 2014;32:1106\u201312.","journal-title":"Nat Biotechnol"},{"key":"1316_CR87","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-023-06834-7","volume":"625","author":"D Huang","year":"2024","unstructured":"Huang D, Zhu X, Ye S, Zhang J, Liao J, Zhang N, et al. Tumor circular RNAs elicit antitumor immunity by encoding cryptic peptides. Nature. 2024;625:593\u2013602.","journal-title":"Nature"},{"key":"1316_CR88","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","volume":"46","author":"JG Abelin","year":"2017","unstructured":"Abelin JG, Keskin DB, Sarkizova S, Hartigan CR, Zhang W, Sidney J, et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity. 2017;46:315\u201326.","journal-title":"Immunity"},{"key":"1316_CR89","doi-asserted-by":"publisher","unstructured":"Huber F, Arnaud M, Stevenson BJ, Michaux J, Benedetti F, Thevenet J, et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat Biotechnol. 2024. https:\/\/doi.org\/10.1038\/s41587-024-02420-y.","DOI":"10.1038\/s41587-024-02420-y"},{"key":"1316_CR90","doi-asserted-by":"publisher","first-page":"e1005725","DOI":"10.1371\/journal.pcbi.1005725","volume":"13","author":"M Bassani-Sternberg","year":"2017","unstructured":"Bassani-Sternberg M, Chong C, Guillaume P, Solleder M, Pak H, Gannon PO, et al. Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS Comput Biol. 2017;13:e1005725.","journal-title":"PLoS Comput Biol"},{"key":"1316_CR91","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41587-019-0289-6","volume":"37","author":"J Racle","year":"2019","unstructured":"Racle J, Michaux J, Rockinger GA, Arnaud M, Bobisse S, Chong C, et al. Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nat Biotechnol. 2019;37:1283\u20136.","journal-title":"Nat Biotechnol"},{"key":"1316_CR92","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199:3360\u20138.","journal-title":"J Immunol"},{"key":"1316_CR93","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/imm.12889","volume":"154","author":"KK Jensen","year":"2018","unstructured":"Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, et al. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 2018;154:394\u2013406.","journal-title":"Immunology"},{"key":"1316_CR94","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.4049\/jimmunol.1800914","volume":"201","author":"D Gfeller","year":"2018","unstructured":"Gfeller D, Guillaume P, Michaux J, Pak HS, Daniel RT, Racle J, et al. The length distribution and multiple specificity of naturally, presented HLA-I ligands. J Immunol. 2018;201:3705\u201316.","journal-title":"J Immunol"},{"key":"1316_CR95","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1074\/mcp.M114.042812","volume":"14","author":"M Bassani-Sternberg","year":"2015","unstructured":"Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteom. 2015;14:658\u201373.","journal-title":"Mol Cell Proteom"},{"key":"1316_CR96","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung. Cancer Cancer Discov. 2017;7:264\u201376.","journal-title":"Cancer Cancer Discov"},{"key":"1316_CR97","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34:525\u20137.","journal-title":"Nat Biotechnol"},{"key":"1316_CR98","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cels.2019.08.009","volume":"9","author":"LP Richman","year":"2019","unstructured":"Richman LP, Vonderheide RH, Rech AJ. Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade. Cell Syst. 2019;9:375\u2013382.e4.","journal-title":"Cell Syst"},{"key":"1316_CR99","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran VP, \u0141uksza M, Zhao JN, Makarov V, Moral JA, Remark R, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551:512\u20136.","journal-title":"Nature"},{"key":"1316_CR100","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature24473","volume":"551","author":"M \u0141uksza","year":"2017","unstructured":"\u0141uksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, et al. A neoantigen fitness model predicts tumor response to checkpoint blockade immunotherapy. Nature. 2017;551:517\u201320.","journal-title":"Nature"},{"key":"1316_CR101","doi-asserted-by":"publisher","first-page":"B003","DOI":"10.1158\/1538-7445.CRC22-B003","volume":"82","author":"R Poudel","year":"2022","unstructured":"Poudel R, Dai D, Li F, Yin X, Kou Y, Gomes ALC. Abstract B003: Cross-reacting antigens between the intestinal microbiome and tumor neoantigen are associated with immune checkpoint inhibitor response in a gastrointestinal tumor cohort. Cancer Res. 2022;82:B003\u2013B003.","journal-title":"Cancer Res"},{"key":"1316_CR102","doi-asserted-by":"publisher","first-page":"102171","DOI":"10.1016\/j.coi.2022.102171","volume":"75","author":"L Zitvogel","year":"2022","unstructured":"Zitvogel L, Kroemer G. Cross-reactivity between microbial and tumor antigens. Curr Opin Immunol. 2022;75:102171.","journal-title":"Curr Opin Immunol"},{"key":"1316_CR103","doi-asserted-by":"crossref","unstructured":"Roerden M, Castro AB, Cui Y, Harake N, Kim B, Dye J, et al. Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression. J Immunother Cancer. 2024;12:e010249.","DOI":"10.1136\/jitc-2024-010249"},{"key":"1316_CR104","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1126\/science.aac7041","volume":"350","author":"T Wang","year":"2015","unstructured":"Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, et al. Identification and characterization of essential genes in the human genome. Science. 2015;350:1096\u2013101.","journal-title":"Science"},{"key":"1316_CR105","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko V, Rosenberg SA. Identifying and targeting human tumor antigens for T-cell-based immunotherapy of solid tumors. Cancer Cell. 2020;38:454\u201372.","journal-title":"Cancer Cell"},{"key":"1316_CR106","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.tig.2024.09.003","volume":"41","author":"E Kina","year":"2024","unstructured":"Kina E, Larouche JD, Thibault P, Perreault C. The cryptic immunopeptidome in health and disease. Trends Genet. 2024;41:162\u20139.","journal-title":"Trends Genet"},{"key":"1316_CR107","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12434","volume":"272","author":"SR Starck","year":"2016","unstructured":"Starck SR, Shastri N. Nowhere to hide: unconventional translation yields cryptic peptides for immune surveillance. Immunol Rev. 2016;272:8\u201316.","journal-title":"Immunol Rev"},{"key":"1316_CR108","doi-asserted-by":"publisher","first-page":"eadk3487","DOI":"10.1126\/science.adk3487","volume":"388","author":"ZA Ely","year":"2025","unstructured":"Ely ZA, Kulstad ZJ, Gunaydin G, Addepalli S, Verzani EK, Casarrubios M, et al. Pancreatic cancer\u2013restricted cryptic antigens are targets for T-cell recognition. Science. 2025;388:eadk3487.","journal-title":"Science"},{"key":"1316_CR109","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41580-023-00674-z","volume":"25","author":"N Dopkins","year":"2024","unstructured":"Dopkins N, Nixon DF. Activation of human endogenous retroviruses and its physiological consequences. Nat Rev Mol Cell Biol. 2024;25:212\u201322.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1316_CR110","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3389\/fonc.2013.00243","volume":"3","author":"E Cherkasova","year":"2013","unstructured":"Cherkasova E, Weisman Q, Childs RW. Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors. Front Oncol. 2013;3:243.","journal-title":"Front Oncol"},{"key":"1316_CR111","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1172\/JCI121476","volume":"128","author":"CC Smith","year":"2018","unstructured":"Smith CC, Beckermann KE, Bortone DS, De Cubas AA, Bixby LM, Lee SJ, et al. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest. 2018;128:4804\u201320.","journal-title":"J Clin Invest"},{"key":"1316_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19464-8","volume":"11","author":"SK Saini","year":"2020","unstructured":"Saini SK, \u00d8rskov AD, Bjerregaard AM, Unnikrishnan A, Holmberg-Thyd\u00e9n S, Borch A, et al. Human endogenous retroviruses form a reservoir of T-cell targets in hematological cancers. Nat Commun. 2020;11:5660.","journal-title":"Nat Commun"},{"key":"1316_CR113","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.cell.2025.01.046","volume":"188","author":"Q Jiang","year":"2025","unstructured":"Jiang Q, Braun DA, Clauser KR, Ramesh V, Shirole NH, Duke-Cohan JE, et al. HIF regulates multiple translated endogenous retroviruses: implications for cancer immunotherapy. Cell. 2025;188:1807\u20131827.e34.","journal-title":"Cell"},{"key":"1316_CR114","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-023-05771-9","volume":"616","author":"KW Ng","year":"2023","unstructured":"Ng KW, Boumelha J, Enfield K, Almagro J, Cha H, Pich O, et al. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature. 2023;616:563\u201373.","journal-title":"Nature"},{"key":"1316_CR115","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41571-021-00585-y","volume":"19","author":"LS Kristensen","year":"2022","unstructured":"Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022;19:188\u2013206.","journal-title":"Nat Rev Clin Oncol"},{"key":"1316_CR116","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0952-7915(03)00083-9","volume":"15","author":"A Sette","year":"2003","unstructured":"Sette A, Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol. 2003;15:461\u201370.","journal-title":"Curr Opin Immunol"},{"key":"1316_CR117","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nrd2224","volume":"6","author":"AW Purcell","year":"2007","unstructured":"Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov. 2007;6:404\u201314.","journal-title":"Nat Rev Drug Discov"},{"key":"1316_CR118","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.drudis.2022.03.004","volume":"27","author":"P Kalita","year":"2022","unstructured":"Kalita P, Tripathi T. Methodological advances in the design of peptide-based vaccines. Drug Discov Today. 2022;27:1367\u201380.","journal-title":"Drug Discov Today"},{"key":"1316_CR119","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coi.2020.08.008","volume":"65","author":"SG Reed","year":"2020","unstructured":"Reed SG, Tomai M, Gale MJ Jr. New horizons in adjuvants for vaccine development. Curr Opin Immunol. 2020;65:97\u2013101.","journal-title":"Curr Opin Immunol"},{"key":"1316_CR120","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10:787\u201396.","journal-title":"Nat Rev Immunol"},{"key":"1316_CR121","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","volume":"17","author":"JF Vansteenkiste","year":"2016","unstructured":"Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (MAGRIT): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:822\u201335.","journal-title":"Lancet Oncol"},{"key":"1316_CR122","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.ejca.2015.07.035","volume":"51","author":"G Giaccone","year":"2015","unstructured":"Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juh\u00e1sz E, Ramlau R, et al. A phase III study of belagenpumatucel-L, an allogeneic tumor cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015;51:2321\u20139.","journal-title":"Eur J Cancer"},{"key":"1316_CR123","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","volume":"15","author":"C Butts","year":"2014","unstructured":"Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase 3 trial. Lancet Oncol. 2014;15:59\u201368.","journal-title":"Lancet Oncol"},{"key":"1316_CR124","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/S1470-2045(16)30408-9","volume":"17","author":"BI Rini","year":"2016","unstructured":"Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicenter, open-label, randomized, controlled, phase 3 trial. Lancet Oncol. 2016;17:1599\u2013611.","journal-title":"Lancet Oncol"},{"key":"1316_CR125","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","volume":"15","author":"G Middleton","year":"2014","unstructured":"Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomized, phase 3 trial. Lancet Oncol. 2014;15:829\u201340.","journal-title":"Lancet Oncol"},{"key":"1316_CR126","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.immuni.2005.01.010","volume":"22","author":"WL Redmond","year":"2005","unstructured":"Redmond WL, Sherman LA. Peripheral tolerance of CD8 T lymphocytes. Immunity. 2005;22:275\u201384.","journal-title":"Immunity"},{"key":"1316_CR127","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nm.3105","volume":"19","author":"Y Hailemichael","year":"2013","unstructured":"Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, et al. Persistent antigen at vaccination sites induces tumor-specific CD8(\u2009+\u2009) T-cell sequestration, dysfunction and deletion. Nat Med. 2013;19:465\u201372.","journal-title":"Nat Med"},{"key":"1316_CR128","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/eji.200737995","volume":"38","author":"MS Bijker","year":"2008","unstructured":"Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol. 2008;38:1033\u201342.","journal-title":"Eur J Immunol"},{"key":"1316_CR129","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrc2373","volume":"8","author":"CJ Melief","year":"2008","unstructured":"Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8:351\u201360.","journal-title":"Nat Rev Cancer"},{"key":"1316_CR130","doi-asserted-by":"publisher","first-page":"e1560919","DOI":"10.1080\/2162402X.2018.1560919","volume":"8","author":"C Rabu","year":"2019","unstructured":"Rabu C, Rangan L, Florenceau L, Fortun A, Charpentier M, Dupr\u00e9 E, et al. Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T-cell epitopes by dendritic cells. Oncoimmunology. 2019;8:e1560919.","journal-title":"Oncoimmunology"},{"key":"1316_CR131","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.it.2024.02.005","volume":"45","author":"M Guo","year":"2024","unstructured":"Guo M, Liu MYR, Brooks DG. Regulation and impact of tumor-specific CD4(\u2009+\u2009) T cells in cancer and immunotherapy. Trends Immunol. 2024;45:303\u201313.","journal-title":"Trends Immunol"},{"key":"1316_CR132","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1002\/eji.201343324","volume":"43","author":"RA Rosalia","year":"2013","unstructured":"Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol. 2013;43:2554\u201365.","journal-title":"Eur J Immunol"},{"key":"1316_CR133","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.1074\/jbc.M809456200","volume":"284","author":"H Zhang","year":"2009","unstructured":"Zhang H, Hong H, Li D, Ma S, Di Y, Stoten A, et al. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4\u2009+\u2009T cells. J Biol Chem. 2009;284:9184\u201391.","journal-title":"J Biol Chem"},{"key":"1316_CR134","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1016\/S0264-410X(01)00233-X","volume":"19","author":"BD Livingston","year":"2001","unstructured":"Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine. 2001;19:4652\u201360.","journal-title":"Vaccine"},{"key":"1316_CR135","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1084\/jem.188.9.1553","volume":"188","author":"R Dyall","year":"1998","unstructured":"Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, et al. Heteroclitic immunization induces tumor immunity. J Exp Med. 1998;188:1553\u201361.","journal-title":"J Exp Med"},{"key":"1316_CR136","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1074-7613(00)00052-2","volume":"13","author":"JE Slansky","year":"2000","unstructured":"Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity. 2000;13:529\u201338.","journal-title":"Immunity"},{"key":"1316_CR137","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.4049\/jimmunol.153.12.5586","volume":"153","author":"A Sette","year":"1994","unstructured":"Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T-cell epitopes. J Immunol. 1994;153:5586\u201392.","journal-title":"J Immunol"},{"key":"1316_CR138","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.4049\/jimmunol.1000629","volume":"185","author":"DK Cole","year":"2010","unstructured":"Cole DK, Edwards ES, Wynn KK, Clement M, Miles JJ, Ladell K, et al. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T-cell recognition. J Immunol. 2010;185:2600\u201310.","journal-title":"J Immunol"},{"key":"1316_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02757-x","volume":"19","author":"B Cavalluzzo","year":"2021","unstructured":"Cavalluzzo B, Ragone C, Mauriello A, Petrizzo A, Manolio C, Caporale A, et al. Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy. J Transl Med. 2021;19:89.","journal-title":"J Transl Med"},{"key":"1316_CR140","doi-asserted-by":"publisher","first-page":"769799","DOI":"10.3389\/fimmu.2021.769799","volume":"12","author":"M Tagliamonte","year":"2021","unstructured":"Tagliamonte M, Mauriello A, Cavalluzzo B, Ragone C, Manolio C, Luciano A, et al. MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor Response. Front Immunol. 2021;12:769799.","journal-title":"Front Immunol"},{"key":"1316_CR141","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00262-010-0845-x","volume":"59","author":"MJ Ciesielski","year":"2010","unstructured":"Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A, et al. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother. 2010;59:1211\u201321.","journal-title":"Cancer Immunol Immunother"},{"key":"1316_CR142","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0169-409X(98)00008-8","volume":"32","author":"RK Gupta","year":"1998","unstructured":"Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 1998;32:155\u201372.","journal-title":"Adv Drug Deliv Rev"},{"key":"1316_CR143","first-page":"406","volume":"3","author":"H Hogenesch","year":"2012","unstructured":"Hogenesch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol. 2012;3:406.","journal-title":"Front Immunol"},{"key":"1316_CR144","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther. 2023;8:283.","journal-title":"Signal Transduct Target Ther"},{"key":"1316_CR145","doi-asserted-by":"publisher","first-page":"e70008","DOI":"10.1111\/imr.70008","volume":"330","author":"P Gurung","year":"2025","unstructured":"Gurung P. Innate immune sensors in health and disease. Immunol Rev. 2025;330:e70008 p.","journal-title":"Immunol Rev"},{"key":"1316_CR146","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.immuni.2023.07.018","volume":"56","author":"LL Cao","year":"2023","unstructured":"Cao LL, Kagan JC. Targeting innate immune pathways for cancer immunotherapy. Immunity. 2023;56:2206\u201317.","journal-title":"Immunity"},{"key":"1316_CR147","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-immunol-032414-112258","volume":"33","author":"Q Yin","year":"2015","unstructured":"Yin Q, Fu TM, Li J, Wu H. Structural biology of innate immunity. Annu Rev Immunol. 2015;33:393\u2013416.","journal-title":"Annu Rev Immunol"},{"key":"1316_CR148","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T-cell responses in phase Ib glioblastoma trial. Nature. 2019;565:234\u20139.","journal-title":"Nature"},{"key":"1316_CR149","first-page":"347","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell. Lung Cancer, or Bladder Cancer Cell. 2020;183:347\u2013362.e24.","journal-title":"Lung Cancer, or Bladder Cancer Cell"},{"key":"1316_CR150","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu Z, Leet DE, Alles\u00f8e RL, Oliveira G, Li S, Luoma AM, et al. Personal neoantigen vaccines induce persistent memory T-cell responses and epitope spreading in patients with melanoma. Nat Med. 2021;27:515\u201325.","journal-title":"Nat Med"},{"key":"1316_CR151","doi-asserted-by":"publisher","first-page":"101414","DOI":"10.1016\/j.smim.2020.101414","volume":"49","author":"H Sultan","year":"2020","unstructured":"Sultan H, Salazar AM, Celis E. Poly-ICLC, a multifunctional immune modulator for treating cancer. Semin Immunol. 2020;49:101414.","journal-title":"Semin Immunol"},{"key":"1316_CR152","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00262-018-2164-6","volume":"67","author":"H Sultan","year":"2018","unstructured":"Sultan H, Wu J, Kumai T, Salazar AM, Celis E. Role of MDA5 and interferon-I in dendritic cells for T-cell expansion by anti-tumor peptide vaccines in mice. Cancer Immunol Immunother. 2018;67:1091\u2013103.","journal-title":"Cancer Immunol Immunother"},{"key":"1316_CR153","doi-asserted-by":"crossref","unstructured":"Wang P. Natural and Synthetic Saponins as Vaccine Adjuvants. Vaccines (Basel). 2021;9:222.","DOI":"10.3390\/vaccines9030222"},{"key":"1316_CR154","doi-asserted-by":"publisher","first-page":"152905","DOI":"10.1016\/j.phymed.2019.152905","volume":"60","author":"MA Lacaille-Dubois","year":"2019","unstructured":"Lacaille-Dubois MA. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review. Phytomedicine. 2019;60:152905.","journal-title":"Phytomedicine"},{"key":"1316_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13324","volume":"7","author":"MH den Brok","year":"2016","unstructured":"den Brok MH, B\u00fcll C, Wassink M, de Graaf AM, Wagenaars JA, Minderman M, et al. Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. Nat Commun. 2016;7:13324.","journal-title":"Nat Commun"},{"key":"1316_CR156","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01056-y","volume":"10","author":"LG Huis In 't Veld","year":"2025","unstructured":"Huis In 't Veld LG, Cornelissen LA, van den Bogaard L, Ansems M, Ho NI, Adema GJ. Saponin-based adjuvant uptake and induction of antigen cross-presentation by CD11b+ dendritic cells and macrophages. npj Vaccines. 2025;10:15.","journal-title":"npj Vaccines"},{"key":"1316_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/srep39475","volume":"6","author":"S Detienne","year":"2016","unstructured":"Detienne S, Welsby I, Collignon C, Wouters S, Coccia M, Delhaye S, et al. Central role of CD169(+) lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01. Sci Rep. 2016;6:39475.","journal-title":"Sci Rep"},{"key":"1316_CR158","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.tips.2018.03.005","volume":"39","author":"DJ Marciani","year":"2018","unstructured":"Marciani DJ. Elucidating the mechanisms of action of saponin-derived adjuvants. Trends Pharm Sci. 2018;39:573\u201385.","journal-title":"Trends Pharm Sci"},{"key":"1316_CR159","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson N, Ablasser A. The cGAS\u2013STING pathway and cancer. Nature Cancer. 2022;3:1452\u201363.","journal-title":"Nature Cancer"},{"key":"1316_CR160","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41586-025-08758-w","volume":"641","author":"X Wang","year":"2025","unstructured":"Wang X, Huang Z, Xing L, Shang L, Jiang J, Deng C, et al. STING agonist-based ER-targeting molecules boost antigen cross-presentation. Nature. 2025;641:202\u201310.","journal-title":"Nature"},{"key":"1316_CR161","doi-asserted-by":"publisher","first-page":"e77846","DOI":"10.1371\/journal.pone.0077846","volume":"8","author":"G Yi","year":"2013","unstructured":"Yi G, Brendel VP, Shu C, Li P, Palanathan S, Cheng Kao C. Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS One. 2013;8:e77846.","journal-title":"PLoS One"},{"key":"1316_CR162","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41551-020-00675-9","volume":"5","author":"S Li","year":"2021","unstructured":"Li S, Luo M, Wang Z, Feng Q, Wilhelm J, Wang X, et al. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nat Biomed Eng. 2021;5:455\u201366.","journal-title":"Nat Biomed Eng"},{"key":"1316_CR163","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jconrel.2020.11.056","volume":"329","author":"J Wilhelm","year":"2021","unstructured":"Wilhelm J, Qui\u00f1ones-P\u00e9rez M, Wang J, Wang X, Basava VS, Gao J. Antigen folding improves loading efficiency and antitumor efficacy of PC7A nanoparticle vaccine. J Control Release. 2021;329:353\u201360.","journal-title":"J Control Release"},{"key":"1316_CR164","doi-asserted-by":"crossref","unstructured":"Niemi JVL, Sokolov AV, Schi\u00f6th HB. Neoantigen Vaccines; Clinical Trials, Classes, Indications, Adjuvants and Combinatorial Treatments. Cancers (Basel). 2022;14:5163.","DOI":"10.3390\/cancers14205163"},{"key":"1316_CR165","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1586\/erv.09.160","volume":"9","author":"M Black","year":"2010","unstructured":"Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev Vaccines. 2010;9:157\u201373.","journal-title":"Expert Rev Vaccines"},{"key":"1316_CR166","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.vaccine.2014.02.027","volume":"32","author":"PO Ilyinskii","year":"2014","unstructured":"Ilyinskii PO, Roy CJ, O'Neil CP, Browning EA, Pittet LA, Altreuter DH, et al. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine. 2014;32:2882\u201395.","journal-title":"Vaccine"},{"key":"1316_CR167","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.apsb.2021.03.007","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang J, Zhu D, Wang Y, Qing G, Zhang Y, et al. Effect of physicochemical properties on in vivo fate of nanoparticle-based cancer immunotherapies. Acta Pharmaceutica Sin B. 2021;11:886\u2013902.","journal-title":"Acta Pharmaceutica Sin B"},{"key":"1316_CR168","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/nbt1332","volume":"25","author":"ST Reddy","year":"2007","unstructured":"Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O'Neil CP, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007;25:1159\u201364.","journal-title":"Nat Biotechnol"},{"key":"1316_CR169","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3762\/bjnano.5.174","volume":"5","author":"DA Kuhn","year":"2014","unstructured":"Kuhn DA, Vanhecke D, Michen B, Blank F, Gehr P, Petri-Fink A, et al. Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages. Beilstein J Nanotechnol. 2014;5:1625\u201336.","journal-title":"Beilstein J Nanotechnol"},{"key":"1316_CR170","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1021\/bm101482r","volume":"12","author":"Z-G Yue","year":"2011","unstructured":"Yue Z-G, Wei W, Lv PP, Yue H, Wang LY, Su ZG, et al. Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles. Biomacromolecules. 2011;12:2440\u20136.","journal-title":"Biomacromolecules"},{"key":"1316_CR171","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s41563-022-01251-z","volume":"21","author":"EL Dane","year":"2022","unstructured":"Dane EL, Belessiotis-Richards A, Backlund C, Wang J, Hidaka K, Milling LE, et al. STING agonist delivery by tumor-penetrating PEG-lipid nanodiscs primes robust anticancer immunity. Nat Mater. 2022;21:710\u201320.","journal-title":"Nat Mater"},{"key":"1316_CR172","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1021\/acsnano.7b07797","volume":"12","author":"R Palomba","year":"2018","unstructured":"Palomba R, Palange AL, Rizzuti IF, Ferreira M, Cervadoro A, Barbato MG, et al. Modulating phagocytic cell sequestration by tailoring nanoconstruct softness. ACS Nano. 2018;12:1433\u201344.","journal-title":"ACS Nano"},{"key":"1316_CR173","first-page":"81","volume":"10","author":"J Li","year":"2015","unstructured":"Li J, Wang X, Zhang T, Wang C, Huang Z, Luo X, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015;10:81\u201398.","journal-title":"Asian J Pharm Sci"},{"key":"1316_CR174","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2147\/IJN.S125866","volume":"12","author":"J Gao","year":"2017","unstructured":"Gao J, Ochyl LJ, Yang E, Moon JJ. Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens. Int J Nanomed. 2017;12:1251\u201364.","journal-title":"Int J Nanomed"},{"key":"1316_CR175","doi-asserted-by":"crossref","unstructured":"Heuts J, Jiskoot W, Ossendorp F, van der Maaden K. Cationic Nanoparticle-Based Cancer Vaccines. Pharmaceutics. 2021;13:596.","DOI":"10.3390\/pharmaceutics13050596"},{"key":"1316_CR176","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.1039\/D4TB00186A","volume":"12","author":"Y Gao","year":"2024","unstructured":"Gao Y, Huang Y, Ren C, Chou P, Wu C, Pan X, et al. Looking back, moving forward: protein corona of lipid nanoparticles. J Mater Chem B. 2024;12:5573\u201388.","journal-title":"J Mater Chem B"},{"key":"1316_CR177","doi-asserted-by":"publisher","first-page":"114635","DOI":"10.1016\/j.addr.2022.114635","volume":"192","author":"W Kim","year":"2023","unstructured":"Kim W, Ly NK, He Y, Li Y, Yuan Z, Yeo Y. Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery. Adv Drug Deliv Rev. 2023;192:114635.","journal-title":"Adv Drug Deliv Rev"},{"key":"1316_CR178","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jconrel.2022.09.002","volume":"351","author":"S Zalba","year":"2022","unstructured":"Zalba S, Ten Hagen T, Burgui C, Garrido MJ. Stealth nanoparticles in oncology: facing the PEG dilemma. J Control Release. 2022;351:22\u201336.","journal-title":"J Control Release"},{"key":"1316_CR179","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1073\/pnas.2109256118","volume":"118","author":"SA Dilliard","year":"2021","unstructured":"Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci USA. 2021;118:52.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1316_CR180","doi-asserted-by":"publisher","first-page":"e09394","DOI":"10.1016\/j.heliyon.2022.e09394","volume":"8","author":"H Nsairat","year":"2022","unstructured":"Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8:e09394.","journal-title":"Heliyon"},{"key":"1316_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27493-0","volume":"12","author":"X Han","year":"2021","unstructured":"Han X, Zhang H, Butowska K, Swingle KL, Alameh MG, Weissman D, et al. An ionizable lipid toolbox for RNA delivery. Nat Commun. 2021;12:7233.","journal-title":"Nat Commun"},{"key":"1316_CR182","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jconrel.2019.06.025","volume":"307","author":"H Abumanhal-Masarweh","year":"2019","unstructured":"Abumanhal-Masarweh H, da Silva D, Poley M, Zinger A, Goldman E, Krinsky N, et al. Tailoring the lipid composition of nanoparticles modulates their cellular uptake and affects the viability of triple negative breast cancer cells. J Controlled Release. 2019;307:331\u201341.","journal-title":"J Controlled Release"},{"key":"1316_CR183","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1021\/acscentsci.2c00227","volume":"8","author":"Z Huang","year":"2022","unstructured":"Huang Z, Callmann CE, Wang S, Vasher MK, Evangelopoulos M, Petrosko SH, et al. Rational vaccinology: harnessing nanoscale chemical design for cancer immunotherapy. ACS Cent Sci. 2022;8:692\u2013704.","journal-title":"ACS Cent Sci"},{"key":"1316_CR184","doi-asserted-by":"crossref","unstructured":"Meckes B, Banga RJ, Nguyen ST, Mirkin CA. Enhancing the Stability and Immunomodulatory Activity of Liposomal Spherical Nucleic Acids through Lipid-Tail DNA Modifications. Small. 2018;14:1702909.","DOI":"10.1002\/smll.201702909"},{"key":"1316_CR185","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nmat4822","volume":"16","author":"R Kuai","year":"2017","unstructured":"Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017;16:489\u201396.","journal-title":"Nat Mater"},{"key":"1316_CR186","doi-asserted-by":"publisher","first-page":"10473","DOI":"10.1073\/pnas.1902805116","volume":"116","author":"S Wang","year":"2019","unstructured":"Wang S, Qin L, Yamankurt G, Skakuj K, Huang Z, Chen PC, et al. Rational vaccinology with spherical nucleic acids. Proc Natl Acad Sci. 2019;116:10473\u201381.","journal-title":"Proc Natl Acad Sci"},{"key":"1316_CR187","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1021\/acscentsci.1c00779","volume":"7","author":"K Skakuj","year":"2021","unstructured":"Skakuj K, Teplensky MH, Wang S, Dittmar JW, Mirkin CA. Chemically tuning the antigen release kinetics from spherical nucleic acids maximizes immune stimulation. ACS Central Science. 2021;7:1838\u201346.","journal-title":"ACS Central Science"},{"key":"1316_CR188","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41551-023-01030-4","volume":"7","author":"LH Rhym","year":"2023","unstructured":"Rhym LH, Manan RS, Koller A, Stephanie G, Anderson DG. Peptide-encoding mRNA barcodes for the high-throughput in vivo screening of libraries of lipid nanoparticles for mRNA delivery. Nat Biomed Eng. 2023;7:901\u201310.","journal-title":"Nat Biomed Eng"},{"key":"1316_CR189","doi-asserted-by":"publisher","first-page":"100572","DOI":"10.1016\/j.crmeth.2023.100572","volume":"3","author":"J Khirallah","year":"2023","unstructured":"Khirallah J, Xu Q. A high-throughput approach of screening nanoparticles for targeted delivery of mRNA. Cell Rep Methods. 2023;3:100572.","journal-title":"Cell Rep Methods"},{"key":"1316_CR190","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41551-019-0351-1","volume":"3","author":"G Yamankurt","year":"2019","unstructured":"Yamankurt G, Berns EJ, Xue A, Lee A, Bagheri N, Mrksich M, et al. Exploration of the nanomedicine-design space with high-throughput screening and machine learning. Nat Biomed Eng. 2019;3:318\u201327.","journal-title":"Nat Biomed Eng"},{"key":"1316_CR191","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/vaccines12080950","volume":"12","author":"D Liu","year":"2024","unstructured":"Liu D, Liu L, Li X, Wang S, Wu G, Che X. Advancements and challenges in peptide-based cancer vaccination: a multidisciplinary perspective. Vaccines (Basel). 2024;12:950.","journal-title":"Vaccines (Basel)"},{"key":"1316_CR192","doi-asserted-by":"publisher","first-page":"e17488","DOI":"10.1016\/j.heliyon.2023.e17488","volume":"9","author":"TC Ezike","year":"2023","unstructured":"Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, et al. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023;9:e17488.","journal-title":"Heliyon"},{"key":"1316_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02191-y","volume":"8","author":"G Zhu","year":"2017","unstructured":"Zhu G, Lynn GM, Jacobson O, Chen K, Liu Y, Zhang H, et al. Albumin\/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat Commun. 2017;8:1954.","journal-title":"Nat Commun"},{"key":"1316_CR194","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1158\/2326-6066.CIR-17-0607","volume":"6","author":"KD Moynihan","year":"2018","unstructured":"Moynihan KD, Holden RL, Mehta NK, Wang C, Karver MR, Dinter J, et al. Enhancement of peptide vaccine immunogenicity by increasing lymphatic drainage and boosting serum stability. Cancer Immunol Res. 2018;6:1025\u201338.","journal-title":"Cancer Immunol Res"},{"key":"1316_CR195","doi-asserted-by":"publisher","first-page":"120868","DOI":"10.1016\/j.biomaterials.2021.120868","volume":"275","author":"JT Martin","year":"2021","unstructured":"Martin JT, Hartwell BL, Kumarapperuma SC, Melo MB, Carnathan DG, Cossette BJ, et al. Combined PET and whole-tissue imaging of lymphatic-targeting vaccines in nonhuman primates. Biomaterials. 2021;275:120868.","journal-title":"Biomaterials"},{"key":"1316_CR196","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186:3148\u20133165.e20.","journal-title":"Cell"},{"key":"1316_CR197","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature12978","volume":"507","author":"H Liu","year":"2014","unstructured":"Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507:519\u201322.","journal-title":"Nature"},{"key":"1316_CR198","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024;30:531\u201342.","journal-title":"Nat Med"},{"key":"1316_CR199","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","volume":"11","author":"I Melero","year":"2014","unstructured":"Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11:509\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"1316_CR200","doi-asserted-by":"crossref","unstructured":"Zom GG, Welters MJ, Loof NM, Goedemans R, Lougheed S, Valentijn RR, et al. TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients. Oncotarget 2016;7:67087\u2013100.","DOI":"10.18632\/oncotarget.11512"},{"key":"1316_CR201","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.coi.2020.01.006","volume":"65","author":"EN Gary","year":"2020","unstructured":"Gary EN, Weiner DB. DNA vaccines: prime time is now. Curr Opin Immunol. 2020;65:21\u201327.","journal-title":"Curr Opin Immunol"},{"key":"1316_CR202","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu C, Shi Q, Huang X, Koo S, Kong N, Tao W. mRNA-based cancer therapeutics. Nat Rev Cancer. 2023;23:526\u201343.","journal-title":"Nat Rev Cancer"},{"key":"1316_CR203","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1093\/nar\/12.18.7035","volume":"12","author":"DA Melton","year":"1984","unstructured":"Melton DA, Krieg PA, Rebagliati MR, Maniatis T, Zinn K, Green MR. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res. 1984;12:7035\u201356.","journal-title":"Nucleic Acids Res"},{"key":"1316_CR204","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"2471","author":"JA Wolff","year":"1990","unstructured":"Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;2471:1465\u20138.","journal-title":"Science"},{"key":"1316_CR205","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/eji.1830230749","volume":"23","author":"F Martinon","year":"1993","unstructured":"Martinon F, Krishnan S, Lenzen G, Magn\u00e9 R, Gomard E, Guillet JG, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol. 1993;23:1719\u201322.","journal-title":"Eur J Immunol"},{"key":"1316_CR206","first-page":"1397","volume":"55","author":"RM Conry","year":"1995","unstructured":"Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 1995;55:1397\u2013400.","journal-title":"Cancer Res"},{"key":"1316_CR207","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3 K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23:165\u201375.","journal-title":"Immunity"},{"key":"1316_CR208","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3 K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16:1833\u201340.","journal-title":"Mol Ther"},{"key":"1316_CR209","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.1093\/nar\/gkq347","volume":"38","author":"BR Anderson","year":"2010","unstructured":"Anderson BR, Muramatsu H, Nallagatla SR, Bevilacqua PC, Sansing LH, Weissman D, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010;38:5884\u201392.","journal-title":"Nucleic Acids Res"},{"key":"1316_CR210","doi-asserted-by":"publisher","first-page":"108015","DOI":"10.1016\/j.jbc.2024.108015","volume":"301","author":"L Jin","year":"2024","unstructured":"Jin L, Zhou Y, Zhang S, Chen SJ. mRNA vaccine sequence and structure design and optimization: advances and challenges. J Biol Chem. 2024;301:108015.","journal-title":"J Biol Chem"},{"key":"1316_CR211","doi-asserted-by":"publisher","first-page":"2307187","DOI":"10.1080\/21645515.2024.2307187","volume":"20","author":"R Yao","year":"2024","unstructured":"Yao R, Xie C, Xia X. Recent progress in mRNA cancer vaccines. Hum Vaccin Immunother. 2024;20:2307187.","journal-title":"Hum Vaccin Immunother"},{"key":"1316_CR212","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41587-019-0164-5","volume":"37","author":"PJ Sample","year":"2019","unstructured":"Sample PJ, Wang B, Reid DW, Presnyak V, McFadyen IJ, Morris DR, et al. Human 5\u2019 UTR design and variant effect prediction from a massively parallel translation assay. Nat Biotechnol. 2019;37:803\u20139.","journal-title":"Nat Biotechnol"},{"key":"1316_CR213","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1021\/acs.accounts.1c00621","volume":"55","author":"SM Castillo-Hair","year":"2022","unstructured":"Castillo-Hair SM, Seelig G. Machine learning for designing next-generation mRNA therapeutics. Acc Chem Res. 2022;55:24\u201334.","journal-title":"Acc Chem Res"},{"key":"1316_CR214","doi-asserted-by":"publisher","first-page":"149254","DOI":"10.1016\/j.gene.2025.149254","volume":"942","author":"T Li","year":"2025","unstructured":"Li T, Liu G, Bu G, Xu Y, He C, Zhao G. Optimizing mRNA translation efficiency through rational 5\u2032UTR and 3\u2032UTR combinatorial design. Gene. 2025;942:149254.","journal-title":"Gene"},{"key":"1316_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70792-x","volume":"14","author":"Q Ma","year":"2024","unstructured":"Ma Q, Zhang X, Yang J, Li H, Hao Y, Feng X. Optimization of the 5\u2019 untranslated region of mRNA vaccines. Sci Rep. 2024;14:19845.","journal-title":"Sci Rep"},{"key":"1316_CR216","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.cell.2015.02.029","volume":"160","author":"V Presnyak","year":"2015","unstructured":"Presnyak V, Alhusaini N, Chen YH, Martin S, Morris N, Kline N, et al. Codon optimality is a major determinant of mRNA stability. Cell. 2015;160:1111\u201324.","journal-title":"Cell"},{"key":"1316_CR217","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature. 2023;621:396\u2013403.","journal-title":"Nature"},{"key":"1316_CR218","doi-asserted-by":"publisher","first-page":"10604","DOI":"10.1093\/nar\/gkab764","volume":"49","author":"HK Wayment-Steele","year":"2021","unstructured":"Wayment-Steele HK, Kim DS, Choe CA, Nicol JJ, Wellington-Oguri R, Watkins AM, et al. Theoretical basis for stabilizing messenger RNA through secondary structure design. Nucleic Acids Res. 2021;49:10604\u201317.","journal-title":"Nucleic Acids Res"},{"key":"1316_CR219","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28776-w","volume":"13","author":"K Leppek","year":"2022","unstructured":"Leppek K, Byeon GW, Kladwang W, Wayment-Steele HK, Kerr CH, Xu AF, et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat Commun. 2022;13:1536.","journal-title":"Nat Commun"},{"key":"1316_CR220","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, et al. MHC-II neoantigens shape tumor immunity and response to immunotherapy. Nature. 2019;574:696\u2013701.","journal-title":"Nature"},{"key":"1316_CR221","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1261\/rna.069286.118","volume":"25","author":"Z Trepotec","year":"2019","unstructured":"Trepotec Z, Geiger J, Plank C, Aneja MK, Rudolph C. Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life. Rna. 2019;25:507\u201318.","journal-title":"Rna"},{"key":"1316_CR222","doi-asserted-by":"crossref","unstructured":"Xia X. Detailed Dissection and Critical Evaluation of the Pfizer\/BioNTech and Moderna mRNA Vaccines. Vaccines (Basel). 2021;9:734.","DOI":"10.3390\/vaccines9070734"},{"key":"1316_CR223","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.omtn.2022.10.003","volume":"30","author":"CY Li","year":"2022","unstructured":"Li CY, Liang Z, Hu Y, Zhang H, Setiasabda KD, Li J, et al. Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in vivo. Mol Ther Nucleic Acids. 2022;30:300\u201310.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1316_CR224","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/15476286.2015.1020271","volume":"12","author":"LL Chen","year":"2015","unstructured":"Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12:381\u20138.","journal-title":"RNA Biol"},{"key":"1316_CR225","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","volume":"348","author":"X Liu","year":"2022","unstructured":"Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G. Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J Control Release. 2022;348:84\u201394.","journal-title":"J Control Release"},{"key":"1316_CR226","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ymeth.2021.02.020","volume":"196","author":"P Obi","year":"2021","unstructured":"Obi P, Chen YG. The design and synthesis of circular RNAs. Methods. 2021;196:85\u2013103.","journal-title":"Methods"},{"key":"1316_CR227","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.7150\/thno.77350","volume":"12","author":"H Li","year":"2022","unstructured":"Li H, Peng K, Yang K, Ma W, Qi S, Yu X, et al. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics. 2022;12:6422\u201336.","journal-title":"Theranostics"},{"key":"1316_CR228","doi-asserted-by":"publisher","first-page":"e2302191120","DOI":"10.1073\/pnas.2302191120","volume":"120","author":"L Amaya","year":"2023","unstructured":"Amaya L, Grigoryan L, Li Z, Lee A, Wender PA, Pulendran B, et al. Circular RNA vaccine induces potent T-cell responses. Proc Natl Acad Sci USA. 2023;120:e2302191120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1316_CR229","doi-asserted-by":"crossref","unstructured":"Lundstrom K. Self-Amplifying RNA Viruses as RNA Vaccines. Int J Mol Sci. 2020;21:5130.","DOI":"10.3390\/ijms21145130"},{"key":"1316_CR230","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","volume":"28","author":"T Beissert","year":"2020","unstructured":"Beissert T, Perkovic M, Vogel A, Erbar S, Walzer KC, Hempel T, et al. A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol Ther. 2020;28:119\u201328.","journal-title":"Mol Ther"},{"key":"1316_CR231","doi-asserted-by":"publisher","first-page":"107534","DOI":"10.1016\/j.biotechadv.2020.107534","volume":"40","author":"Y Weng","year":"2020","unstructured":"Weng Y, Li C, Yang T, Hu B, Zhang M, Guo S, et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv. 2020;40:107534.","journal-title":"Biotechnol Adv"},{"key":"1316_CR232","doi-asserted-by":"publisher","first-page":"e2303261","DOI":"10.1002\/adma.202303261","volume":"35","author":"Y Zong","year":"2023","unstructured":"Zong Y, Lin Y, Wei T, Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater. 2023;35:e2303261.","journal-title":"Adv Mater"},{"key":"1316_CR233","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403\u201316.","journal-title":"N Engl J Med"},{"key":"1316_CR234","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"1316_CR235","doi-asserted-by":"publisher","first-page":"9023","DOI":"10.1039\/C9NR02004G","volume":"11","author":"JA Kulkarni","year":"2019","unstructured":"Kulkarni JA, Witzigmann D, Leung J, van der Meel R, Zaifman J, Darjuan MM, et al. Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads. Nanoscale. 2019;11:9023\u201331.","journal-title":"Nanoscale"},{"key":"1316_CR236","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","volume":"20","author":"E Kon","year":"2023","unstructured":"Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D. Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat Rev Clin Oncol. 2023;20:739\u201354.","journal-title":"Nat Rev Clin Oncol"},{"key":"1316_CR237","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","volume":"154-155","author":"E Samaridou","year":"2020","unstructured":"Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: Current perspectives. Adv Drug Deliv Rev. 2020;154-155:37\u201363. p.","journal-title":"Adv Drug Deliv Rev"},{"key":"1316_CR238","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"1316_CR239","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1038\/mtna.2013.66","volume":"2","author":"BL Mui","year":"2013","unstructured":"Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YY, et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucleic Acids. 2013;2:e139.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1316_CR240","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1248\/bpb.b13-00059","volume":"36","author":"H Hatakeyama","year":"2013","unstructured":"Hatakeyama H, Akita H, Harashima H. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull. 2013;36:892\u20139.","journal-title":"Biol Pharm Bull"},{"key":"1316_CR241","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2217\/nnm-2016-0275","volume":"11","author":"S Grabbe","year":"2016","unstructured":"Grabbe S, Haas H, Diken M, Kranz LM, Langguth P, Sahin U. Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma. Nanomed (Lond). 2016;11:2723\u201334.","journal-title":"Nanomed (Lond)"},{"key":"1316_CR242","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy. Nature. 2016;534:396\u2013401.","journal-title":"Nature"},{"key":"1316_CR243","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.biomaterials.2017.02.019","volume":"125","author":"S Persano","year":"2017","unstructured":"Persano S, Guevara ML, Li Z, Mai J, Ferrari M, Pompa PP, et al. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials. 2017;125:81\u201389.","journal-title":"Biomaterials"},{"key":"1316_CR244","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","volume":"187","author":"HR Mendez-Gomez","year":"2024","unstructured":"Mendez-Gomez HR, DeVries A, Castillo P, von Roemeling C, Qdaisat S, Stover BD, et al. RNA aggregates harness the danger response for potent cancer immunotherapy. Cell. 2024;187:2521\u20132535 e21.","journal-title":"Cell"},{"key":"1316_CR245","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran B. S.A. P, and D.T. O\u2019Hagan, Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20:454\u201375.","journal-title":"Nat Rev Drug Discov"},{"key":"1316_CR246","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","volume":"55","author":"R Verbeke","year":"2022","unstructured":"Verbeke R, Hogan MJ, Lor\u00e9 K, Pardi N. Innate immune mechanisms of mRNA vaccines. Immunity. 2022;55:1993\u20132005.","journal-title":"Immunity"},{"key":"1316_CR247","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.biochi.2007.03.001","volume":"89","author":"MA Garc\u00eda","year":"2007","unstructured":"Garc\u00eda MA, Meurs EF, Esteban M. The dsRNA protein kinase PKR: virus and cell control. Biochimie. 2007;89:799\u2013811.","journal-title":"Biochimie"},{"key":"1316_CR248","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472:481\u20135.","journal-title":"Nature"},{"key":"1316_CR249","doi-asserted-by":"publisher","first-page":"e2214320120","DOI":"10.1073\/pnas.2214320120","volume":"120","author":"TA Tockary","year":"2023","unstructured":"Tockary TA, Abbasi S, Matsui-Masai M, Hayashi A, Yoshinaga N, Boonstra E, et al. Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment. Proc Natl Acad Sci USA. 2023;120:e2214320120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1316_CR250","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","volume":"54","author":"MG Alameh","year":"2021","unstructured":"Alameh MG, Tomb\u00e1cz I, Bettini E, Lederer K, Sittplangkoon C, Wilmore JR, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54:2877\u20132892 e7.","journal-title":"Immunity"},{"key":"1316_CR251","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","volume":"37","author":"L Miao","year":"2019","unstructured":"Miao L, Li L, Huang Y, Delcassian D, Chahal J, Han J, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019;37:1174\u201385.","journal-title":"Nat Biotechnol"},{"key":"1316_CR252","doi-asserted-by":"crossref","unstructured":"Zhang H, You X, Wang X, Cui L, Wang Z, Xu F, et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc Natl Acad Sci USA 2021;118:e2005191118.","DOI":"10.1073\/pnas.2005191118"},{"key":"1316_CR253","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","volume":"16","author":"Y Ju","year":"2022","unstructured":"Ju Y, Lee WS, Pilkington EH, Kelly HG, Li S, Selva KJ, et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano. 2022;16:11769\u201380.","journal-title":"ACS Nano"},{"key":"1316_CR254","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","volume":"23","author":"C Li","year":"2022","unstructured":"Li C, Lee A, Grigoryan L, Arunachalam PS, Scott M, Trisal M, et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat Immunol. 2022;23:543\u201355.","journal-title":"Nat Immunol"},{"key":"1316_CR255","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.aay3638","volume":"371","author":"C Krienke","year":"2021","unstructured":"Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021;371:145\u201353.","journal-title":"Science"},{"key":"1316_CR256","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen S, Tong AJ, Himmels P, Oh J, Paler-Martinez A, Kim L, et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022;23:532\u201342.","journal-title":"Nat Immunol"},{"key":"1316_CR257","doi-asserted-by":"publisher","first-page":"e2207841119","DOI":"10.1073\/pnas.2207841119","volume":"119","author":"J Chen","year":"2022","unstructured":"Chen J, Ye Z, Huang C, Qiu M, Song D, Li Y, et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(\u2009+\u2009) T-cell response. Proc Natl Acad Sci USA. 2022;119:e2207841119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1316_CR258","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2012Cas gene editing. Nat Nanotechnol. 2020;15:313\u201320.","journal-title":"Nat Nanotechnol"},{"key":"1316_CR259","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6:1078\u201394.","journal-title":"Nat Rev Mater"},{"key":"1316_CR260","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","volume":"23","author":"D Bitounis","year":"2024","unstructured":"Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat Rev Drug Discov. 2024;23:281\u2013300.","journal-title":"Nat Rev Drug Discov"},{"key":"1316_CR261","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis PR, Felgner PL. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat Rev Drug Discov. 2024;23:709\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"1316_CR262","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","volume":"3","author":"M Mehta","year":"2023","unstructured":"Mehta M, Bui TA, Yang X, Aksoy Y, Goldys EM, Deng W. Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. ACS Mater Au. 2023;3:600\u201319.","journal-title":"ACS Mater Au"},{"key":"1316_CR263","doi-asserted-by":"publisher","unstructured":"Luozhong S, Liu P, Li R, Yuan Z, Debley E, Chen Y, et al. Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity. Nat Mater. 2025. https:\/\/doi.org\/10.1038\/s41563-025-02240-8.","DOI":"10.1038\/s41563-025-02240-8"},{"key":"1316_CR264","doi-asserted-by":"crossref","unstructured":"Omo-Lamai S, Wang Y, Patel MN, Essien EO, Shen M, Majumdar A, et al. Lipid nanoparticle-associated inflammation is triggered by sensing of endosomal damage: engineering endosomal escape without side effects. bioRxiv, 2024 2024.04.16.589801.","DOI":"10.1101\/2024.04.16.589801"},{"key":"1316_CR265","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jconrel.2024.08.016","volume":"374","author":"BD Barbieri","year":"2024","unstructured":"Barbieri BD, Peeler DJ, Samnuan K, Day S, Hu K, Sallah HJ, et al. The role of helper lipids in optimizing nanoparticle formulations of self-amplifying RNA. J Controlled Release. 2024;374:280\u201392.","journal-title":"J Controlled Release"},{"key":"1316_CR266","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","volume":"11","author":"S Patel","year":"2020","unstructured":"Patel S, Ashwanikumar N, Robinson E, Xia Y, Mihai C, Griffith JP, et al. Naturally occurring cholesterol analogs in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat Commun. 2020;11:983.","journal-title":"Nat Commun"},{"key":"1316_CR267","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41587-024-02174-7","volume":"43","author":"H Chen","year":"2025","unstructured":"Chen H, Liu D, Guo J, Aditham A, Zhou Y, Tian J, et al. Branched chemically modified poly(A) tails enhance the translation capacity of mRNA. Nat Biotechnol. 2025;43:194\u2013203.","journal-title":"Nat Biotechnol"},{"key":"1316_CR268","doi-asserted-by":"publisher","unstructured":"Chen H, Liu D, Aditham A, Guo J, Huang J, Kostas F, et al. Chemical and topological design of multicapped mRNA and capped circular RNA to augment translation. Nat Biotechnol. 2024. https:\/\/doi.org\/10.1038\/s41587-024-02393-y.","DOI":"10.1038\/s41587-024-02393-y"},{"key":"1316_CR269","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41586-025-08842-1","volume":"641","author":"PS Krawczyk","year":"2025","unstructured":"Krawczyk PS, Mazur M, Orze\u0142 W, Gewartowska O, Jele\u0144 S, Antczak W, et al. Readenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines. Nature. 2025;641:984\u201392.","journal-title":"Nature"},{"key":"1316_CR270","doi-asserted-by":"crossref","unstructured":"Peng K, Zhao X, Li H, Fu YX, Liang Y. Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control. J Exp Med. 2025;222:e20241454.","DOI":"10.1084\/jem.20241454"},{"key":"1316_CR271","doi-asserted-by":"publisher","first-page":"eads1328","DOI":"10.1126\/sciimmunol.ads1328","volume":"10","author":"EA Aunins","year":"2025","unstructured":"Aunins EA, Phan AT, Alameh MG, Dwivedi G, Cruz-Morales E, Christian DA, et al. An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T-cell responses. Sci Immunol. 2025;10:eads1328.","journal-title":"Sci Immunol"},{"key":"1316_CR272","doi-asserted-by":"crossref","unstructured":"Phan AT, Aunins E, Cruz-Morales E, Dwivedi G, Bunkofske M, Eberhard JN, et al. The type I IFN-IL-27 axis promotes mRNA vaccine-induced CD8 (\u2009+\u2009) T-cell responses. bioRxiv. 2025.","DOI":"10.1101\/2025.01.16.633383"},{"key":"1316_CR273","doi-asserted-by":"publisher","first-page":"e02506","DOI":"10.1128\/mbio.02506-23","volume":"14","author":"D Zhivaki","year":"2023","unstructured":"Zhivaki D, Gosselin EA, Sengupta D, Concepcion H, Arinze C, Chow J, et al. mRNAs encoding self-DNA reactive cGAS enhance the immunogenicity of lipid nanoparticle vaccines. mBio. 2023;14:e02506\u201323.","journal-title":"mBio"},{"key":"1316_CR274","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","volume":"26","author":"S Linares-Fern\u00e1ndez","year":"2020","unstructured":"Linares-Fern\u00e1ndez S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA vaccine to balance innate\/adaptive immune response. Trends Mol Med. 2020;26:311\u201323.","journal-title":"Trends Mol Med"},{"key":"1316_CR275","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15476286.2024.2333123","volume":"21","author":"Y Mochida","year":"2024","unstructured":"Mochida Y, Uchida S. mRNA vaccine designs for optimal adjuvanticity and delivery. RNA Biol. 2024;21:1\u201327.","journal-title":"RNA Biol"},{"key":"1316_CR276","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.omtn.2020.09.004","volume":"22","author":"L Van Hoecke","year":"2020","unstructured":"Van Hoecke L, Roose K, Ballegeer M, Zhong Z, Sanders NN, De Koker S, et al. The Opposing effect of type I IFN on the T-cell response by nonmodified mRNA-lipoplex vaccines is determined by the route of administration. Mol Ther Nucleic Acids. 2020;22:373\u201381.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1316_CR277","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/mt.2016.161","volume":"24","author":"A De Beuckelaer","year":"2016","unstructured":"De Beuckelaer A, Pollard C, Van Lint S, Roose K, Van Hoecke L, Naessens T, et al. Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T-cell responses. Mol Ther. 2016;24:2012\u201320.","journal-title":"Mol Ther"},{"key":"1316_CR278","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","volume":"198","author":"T Pepini","year":"2017","unstructured":"Pepini T, Pulichino AM, Carsillo T, Carlson AL, Sari-Sarraf F, Ramsauer K, et al. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J Immunol. 2017;198:4012\u201324.","journal-title":"J Immunol"},{"key":"1316_CR279","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51411-9","volume":"15","author":"S Kim","year":"2024","unstructured":"Kim S, Jeon JH, Kim M, Lee Y, Hwang YH, Park M, et al. Innate immune responses against mRNA vaccine promote cellular immunity through IFN-beta at the injection site. Nat Commun. 2024;15:7226.","journal-title":"Nat Commun"},{"key":"1316_CR280","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1038\/mtna.2016.38","volume":"5","author":"K Broos","year":"2016","unstructured":"Broos K, Van der Jeught K, Puttemans J, Goyvaerts C, Heirman C, Dewitte H, et al. Particle-mediated intravenous delivery of antigen mrna results in strong antigen-specific T-cell responses despite the induction of type I interferon. Mol Ther Nucleic Acids. 2016;5:e326.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1316_CR281","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01135-8","volume":"10","author":"JA Wojcechowskyj","year":"2025","unstructured":"Wojcechowskyj JA, Jong RM, M\u00e4ger I, Flach B, Munson PV, Mukherjee PP, et al. Controlling reactogenicity while preserving immunogenicity from a self-amplifying RNA vaccine by modulating nucleocytoplasmic transport. NPJ Vaccines. 2025;10:85.","journal-title":"NPJ Vaccines"},{"key":"1316_CR282","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48559-6","volume":"9","author":"Y Liu","year":"2019","unstructured":"Liu Y, Chin JM, Choo EL, Phua K. Messenger RNA translation enhancement by immune evasion proteins: a comparative study between EKB (vaccinia virus) and NS1 (influenza A virus). Sci Rep. 2019;9:11972.","journal-title":"Sci Rep"},{"key":"1316_CR283","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1089\/hum.2017.121","volume":"28","author":"T Beissert","year":"2017","unstructured":"Beissert T, Koste L, Perkovic M, Walzer KC, Erbar S, Selmi A, et al. Improvement of in vivo expression of genes delivered by self-amplifying RNA using vaccinia virus immune evasion proteins. Hum Gene Ther. 2017;28:1138\u201346.","journal-title":"Hum Gene Ther"},{"key":"1316_CR284","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.drudis.2015.07.009","volume":"21","author":"J Devoldere","year":"2016","unstructured":"Devoldere J, Dewitte H, De Smedt SC, Remaut K. Evading innate immunity in nonviral mRNA delivery: do not shoot the messenger. Drug Discov Today. 2016;21:11\u201325.","journal-title":"Drug Discov Today"},{"key":"1316_CR285","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.ymthe.2020.11.011","volume":"29","author":"AK Blakney","year":"2021","unstructured":"Blakney AK, McKay PF, Bouton CR, Hu K, Samnuan K, Shattock RJ. Innate inhibiting proteins enhance expression and immunogenicity of self-amplifying RNA. Mol Ther. 2021;29:1174\u201385.","journal-title":"Mol Ther"},{"key":"1316_CR286","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.ymthe.2021.03.002","volume":"29","author":"SW Tse","year":"2021","unstructured":"Tse SW, McKinney K, Walker W, Nguyen M, Iacovelli J, Small C, et al. mRNA-encoded, constitutively active STING(V155M) is a potent genetic adjuvant of antigen-specific CD8(\u2009+\u2009) T cell response. Mol Ther. 2021;29:2227\u201338.","journal-title":"Mol Ther"},{"key":"1316_CR287","doi-asserted-by":"publisher","first-page":"eabq3500","DOI":"10.1126\/sciadv.abq3500","volume":"8","author":"N Fan","year":"2022","unstructured":"Fan N, Chen K, Zhu R, Zhang Z, Huang H, Qin S, et al. Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants. Sci Adv. 2022;8:eabq3500.","journal-title":"Sci Adv"},{"key":"1316_CR288","doi-asserted-by":"publisher","first-page":"TPS9616","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9616","volume":"42","author":"JS Weber","year":"2024","unstructured":"Weber JS, Luke JJ, Carlino MS, Khattak MA, Meehan RS, Brown M, et al. INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma. J Clin Oncol. 2024;42:TPS9616\u2013TPS9616.","journal-title":"J Clin Oncol"},{"key":"1316_CR289","doi-asserted-by":"publisher","first-page":"TPS8116","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8116","volume":"42","author":"JM Lee","year":"2024","unstructured":"Lee JM, Spicer J, Nair S, Khattak A, Brown M, Meehan RS, et al. The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non\u2013small-cell lung cancer (NSCLC). J Clin Oncol. 2024;42:TPS8116\u2013TPS8116.","journal-title":"J Clin Oncol"},{"key":"1316_CR290","doi-asserted-by":"publisher","DOI":"10.1186\/1479-0556-3-6","volume":"3","author":"JP Carralot","year":"2005","unstructured":"Carralot JP, Weide B, Schoor O, Probst J, Scheel B, Teufel R, et al. Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. Genet Vaccines Ther. 2005;3:6.","journal-title":"Genet Vaccines Ther"},{"key":"1316_CR291","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","volume":"3","author":"H K\u00fcbler","year":"2015","unstructured":"K\u00fcbler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study. J Immunother Cancer. 2015;3:26.","journal-title":"J Immunother Cancer"},{"key":"1316_CR292","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1007\/s00018-004-4255-0","volume":"61","author":"JP Carralot","year":"2004","unstructured":"Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci. 2004;61:2418\u201324.","journal-title":"Cell Mol Life Sci"},{"key":"1316_CR293","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/mt.2010.289","volume":"19","author":"SM Rittig","year":"2011","unstructured":"Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther. 2011;19:990\u20139.","journal-title":"Mol Ther"},{"key":"1316_CR294","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, L\u00f6wer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222\u20136.","journal-title":"Nature"},{"key":"1316_CR295","doi-asserted-by":"publisher","first-page":"v408","DOI":"10.1093\/annonc\/mdx376.014","volume":"28","author":"A Stenzl","year":"2017","unstructured":"Stenzl A, Feyerabend S, Syndikus I, Sarosiek T, K\u00fcbler H, Heidenreich A, et al. Results of the randomized, placebo-controlled phase I\/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2017;28:v408\u2013v409.","journal-title":"Ann Oncol"},{"key":"1316_CR296","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","volume":"68","author":"M Sebastian","year":"2019","unstructured":"Sebastian M, Schr\u00f6der A, Scheel B, Hong HS, Muth A, von Boehmer L, et al. A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer. Cancer Immunol Immunother. 2019;68:799\u2013812.","journal-title":"Cancer Immunol Immunother"},{"key":"1316_CR297","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","volume":"7","author":"A Papachristofilou","year":"2019","unstructured":"Papachristofilou A, Hipp MM, Klinkhardt U, Fr\u00fch M, Sebastian M, Weiss C, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2019;7:38.","journal-title":"J Immunother Cancer"},{"key":"1316_CR298","doi-asserted-by":"publisher","first-page":"TPS2676","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2676","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase 1\/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors. J Clin Oncol. 2023;41:TPS2676\u2013TPS2676.","journal-title":"J Clin Oncol"},{"key":"1316_CR299","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350.","journal-title":"Nature"},{"key":"1316_CR300","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al. RNA neoantigen vaccines prime long-lived CD8(\u2009+\u2009) T cells in pancreatic cancer. Nature. 2025;639:1042\u201351.","journal-title":"Nature"},{"key":"1316_CR301","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomized, phase 2b study. Lancet. 2024;403:632\u201344.","journal-title":"Lancet"},{"key":"1316_CR302","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, et al. mRNA vaccine-induced neoantigen-specific T-cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020;130:5976\u201388.","journal-title":"J Clin Invest"},{"key":"1316_CR303","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong SJ, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2022;28:1619\u201329.","journal-title":"Nat Med"},{"key":"1316_CR304","doi-asserted-by":"publisher","first-page":"TPS3635","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3635","volume":"40","author":"JR Hecht","year":"2022","unstructured":"Hecht JR, Shergill A, Goldstein MG, Fang B, Cho MT, Lenz HJ, et al. Phase 2\/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly diagnosed metastatic colorectal cancer (GRANITE). J Clin Oncol. 2022;40:TPS3635\u2013TPS3635.","journal-title":"J Clin Oncol"},{"key":"1316_CR305","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2024;30:1013\u201322.","journal-title":"Nat Med"},{"key":"1316_CR306","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367:446\u201353.","journal-title":"Science"},{"key":"1316_CR307","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29:2844\u201353.","journal-title":"Nat Med"},{"key":"1316_CR308","doi-asserted-by":"publisher","first-page":"S489","DOI":"10.1016\/j.annonc.2024.08.678","volume":"35","author":"JBAG Haanen","year":"2024","unstructured":"Haanen JBAG, Mackensen A, Schultze-Florey C, Alsdorf W, Wagner-Drouet E, Heudobler D, et al. 61\u00b0Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed\/refractory CLDN6+ solid tumors. Ann Oncol. 2024;35:S489\u2013S490.","journal-title":"Ann Oncol"},{"key":"1316_CR309","doi-asserted-by":"publisher","first-page":"983000","DOI":"10.3389\/fimmu.2022.983000","volume":"13","author":"C Sittplangkoon","year":"2022","unstructured":"Sittplangkoon C, Alameh MG, Weissman D, Lin P, Tam YK, Prompetchara E, et al. mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model. Front Immunol. 2022;13:983000.","journal-title":"Front Immunol"},{"key":"1316_CR310","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0092-8674(87)90568-X","volume":"49","author":"JW Kappler","year":"1987","unstructured":"Kappler JW, Roehm N, Marrack P. T-cell tolerance by clonal elimination in the thymus. Cell. 1987;49:273\u201380.","journal-title":"Cell"},{"key":"1316_CR311","doi-asserted-by":"publisher","first-page":"200835","DOI":"10.1016\/j.omton.2024.200835","volume":"32","author":"JF de Graaf","year":"2024","unstructured":"de Graaf JF, Pesic T, Spitzer FS, Oosterhuis K, Camps M, Zoutendijk I, et al. Neoantigen-specific T cell help outperforms nonspecific help in multiantigen DNA vaccination against cancer. Mol Ther Oncol. 2024;32:200835.","journal-title":"Mol Ther Oncol"},{"key":"1316_CR312","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/31002","volume":"393","author":"SP Schoenberger","year":"1998","unstructured":"Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480\u20133.","journal-title":"Nature"},{"key":"1316_CR313","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46877-6","volume":"15","author":"EK Ninmer","year":"2024","unstructured":"Ninmer EK, Zhu H, Chianese-Bullock KA, von Mehren M, Haas NB, Ross MI, et al. Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post hoc analysis of a randomized phase II trial. Nat Commun. 2024;15:2570.","journal-title":"Nat Commun"},{"key":"1316_CR314","first-page":"100500","volume":"19","author":"A Bouazzaoui","year":"2024","unstructured":"Bouazzaoui A, Abdellatif AAH. Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy. Vaccine: X. 2024;19:100500.","journal-title":"Vaccine: X"},{"key":"1316_CR315","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00262-018-02294-5","volume":"68","author":"H Sultan","year":"2019","unstructured":"Sultan H, Kumai T, Nagato T, Wu J, Salazar AM, Celis E. The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. Cancer Immunol Immunother. 2019;68:455\u201366.","journal-title":"Cancer Immunol Immunother"},{"key":"1316_CR316","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41590-020-00810-3","volume":"22","author":"F Baharom","year":"2021","unstructured":"Baharom F, Ramirez-Valdez RA, Tobin K, Yamane H, Dutertre CA, Khalilnezhad A, et al. Intravenous nanoparticle vaccination generates stem-like TCF1(+) neoantigen-specific CD8(\u2009+\u2009) T cells. Nat Immunol. 2021;22:41\u201352.","journal-title":"Nat Immunol"},{"key":"1316_CR317","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/eji.200425599","volume":"35","author":"P Johansen","year":"2005","unstructured":"Johansen P, H\u00e4ffner AC, Koch F, Zepter K, Erdmann I, Maloy K, et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol. 2005;35:568\u201374.","journal-title":"Eur J Immunol"},{"key":"1316_CR318","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1002\/eji.200526124","volume":"35","author":"BR von Beust","year":"2005","unstructured":"von Beust BR, Johansen P, Smith KA, Bot A, Storni T, K\u00fcndig TM. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur J Immunol. 2005;35:1869\u201376.","journal-title":"Eur J Immunol"},{"key":"1316_CR319","doi-asserted-by":"publisher","first-page":"102083","DOI":"10.1016\/j.omtn.2023.102083","volume":"35","author":"KJ Hassett","year":"2024","unstructured":"Hassett KJ, Rajlic IL, Bahl K, White R, Cowens K, Jacquinet E, et al. mRNA vaccine trafficking and resulting protein expression after intramuscular administration. Mol Ther Nucleic Acids. 2024;35:102083.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1316_CR320","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","volume":"170","author":"J Kim","year":"2021","unstructured":"Kim J, Eygeris Y, Gupta M, Sahay G. Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021;170:83\u2013112.","journal-title":"Adv Drug Deliv Rev"},{"key":"1316_CR321","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","volume":"25","author":"F Liang","year":"2017","unstructured":"Liang F, Lindgren G, Lin A, Thompson EA, Ols S, R\u00f6hss J, et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol Ther. 2017;25:2635\u201347","journal-title":"Mol Ther"},{"key":"1316_CR322","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345\u201351.","journal-title":"J Control Release"},{"key":"1316_CR323","doi-asserted-by":"publisher","first-page":"102007","DOI":"10.1016\/j.tmaid.2021.102007","volume":"41","author":"JL Schnyder","year":"2021","unstructured":"Schnyder JL, Garcia Garrido HM, De Pijper CA, Daams JG, Stijnis C, Goorhuis A, et al. Comparison of equivalent fractional vaccine doses delivered by intradermal and intramuscular or subcutaneous routes: a systematic review. Travel Med Infect Dis. 2021;41:102007.","journal-title":"Travel Med Infect Dis"},{"key":"1316_CR324","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","volume":"55","author":"Y Lee","year":"2023","unstructured":"Lee Y, Jeong M, Park J, Jung H, Lee H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp Mol Med. 2023;55:2085\u201396.","journal-title":"Exp Mol Med"},{"key":"1316_CR325","doi-asserted-by":"crossref","unstructured":"Zheng M, Tian Z. Liver-Mediated Adaptive Immune Tolerance. Front Immunol. 2019;10:2525.","DOI":"10.3389\/fimmu.2019.02525"},{"key":"1316_CR326","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","volume":"29","author":"I Tomb\u00e1cz","year":"2021","unstructured":"Tomb\u00e1cz I, Laczk\u00f3 D, Shahnawaz H, Muramatsu H, Natesan A, Yadegari A, et al. Highly efficient CD4\u2009+\u2009T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Mol Ther. 2021;29:3293\u2013304.","journal-title":"Mol Ther"},{"key":"1316_CR327","doi-asserted-by":"publisher","first-page":"eabm7950","DOI":"10.1126\/sciadv.abm7950","volume":"8","author":"FY Su","year":"2022","unstructured":"Su FY, Zhao QH, Dahotre SN, Gamboa L, Bawage SS, Silva Trenkle AD, et al. In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles. Sci Adv. 2022;8:eabm7950.","journal-title":"Sci Adv"},{"key":"1316_CR328","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri3806","volume":"15","author":"J Crouse","year":"2015","unstructured":"Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T-cell responses by type I interferons. Nat Rev Immunol. 2015;15:231\u201342.","journal-title":"Nat Rev Immunol"},{"key":"1316_CR329","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.immuni.2006.08.014","volume":"25","author":"AH van Boxel-Dezaire","year":"2006","unstructured":"van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006;25:361\u201372.","journal-title":"Immunity"},{"key":"1316_CR330","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","volume":"21","author":"EJ Sayour","year":"2024","unstructured":"Sayour EJ, Boczkowski D, Mitchell DA, Nair SK. Cancer mRNA vaccines: clinical advances and future opportunities. Nat Rev Clin Oncol. 2024;21:489\u2013500.","journal-title":"Nat Rev Clin Oncol"},{"key":"1316_CR331","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27:74\u201395.","journal-title":"Cell Res"},{"key":"1316_CR332","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.trecan.2017.12.007","volume":"4","author":"M Saxena","year":"2018","unstructured":"Saxena M, Bhardwaj N. Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer. 2018;4:119\u201337.","journal-title":"Trends Cancer"},{"key":"1316_CR333","doi-asserted-by":"publisher","first-page":"2412876","DOI":"10.1080\/2162402X.2024.2412876","volume":"13","author":"F Borges","year":"2024","unstructured":"Borges F, Laureano RS, Vanmeerbeek I, Sprooten J, Demeulenaere O, Govaerts J, et al. Trial watch: anticancer vaccination with dendritic cells. Oncoimmunology. 2024;13:2412876.","journal-title":"Oncoimmunology"},{"key":"1316_CR334","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-025-01692-4","volume":"18","author":"N Liu","year":"2025","unstructured":"Liu N, Wang X, Wang Z, Kan Y, Fang Y, Gao J, et al. Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy. J Hematol Oncol. 2025;18:45.","journal-title":"J Hematol Oncol"},{"key":"1316_CR335","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","volume":"23","author":"N Gong","year":"2024","unstructured":"Gong N, Alameh MG, El-Mayta R, Xue L, Weissman D, Mitchell MJ. Enhancing in situ cancer vaccines using delivery technologies. Nat Rev Drug Discov. 2024;23:607\u201325.","journal-title":"Nat Rev Drug Discov"},{"key":"1316_CR336","doi-asserted-by":"publisher","first-page":"eaaz4204","DOI":"10.1126\/sciadv.aaz4204","volume":"6","author":"Y Chao","year":"2020","unstructured":"Chao Y, Liang C, Tao H, Du Y, Wu D, Dong Z, et al. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. Sci Adv. 2020;6:eaaz4204.","journal-title":"Sci Adv"},{"key":"1316_CR337","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05102-0","volume":"22","author":"Q Liu","year":"2024","unstructured":"Liu Q, Xu R, Shen J, Tao Y, Shao J, Ke Y, et al. In situ chemoimmunotherapy hydrogel elicits immunogenic cell death and evokes efficient antitumor immune response. J Transl Med. 2024;22:341.","journal-title":"J Transl Med"},{"key":"1316_CR338","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1021\/acsnano.3c10225","volume":"18","author":"P Xu","year":"2024","unstructured":"Xu P, Ma J, Zhou Y, Gu Y, Cheng X, Wang Y, et al. RadIotherapy-triggered In Situ Tumor Vaccination Boosts Checkpoint Blockaded Immune Response Via Antigen-capturing Nanoadjuvants. ACS Nano. 2024;18:1022\u201340.","journal-title":"ACS Nano"},{"key":"1316_CR339","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.biomaterials.2017.08.017","volume":"144","author":"G Liang","year":"2017","unstructured":"Liang G, Jin X, Zhang S, Xing D. RGD peptide-modified fluorescent gold nanoclusters as highly efficient tumor-targeted radiotherapy sensitizers. Biomaterials. 2017;144:95\u2013104.","journal-title":"Biomaterials"},{"key":"1316_CR340","doi-asserted-by":"publisher","first-page":"e2202871","DOI":"10.1002\/adhm.202202871","volume":"12","author":"Y Li","year":"2023","unstructured":"Li Y, Luo Y, Hou L, Huang Z, Wang Y, Zhou S. Antigen-capturing dendritic-cell-targeting nanoparticles for enhanced tumor immunotherapy based on photothermal-therapy-induced in situ vaccination. Adv Healthc Mater. 2023;12:e2202871.","journal-title":"Adv Healthc Mater"},{"key":"1316_CR341","doi-asserted-by":"publisher","first-page":"1279221","DOI":"10.3389\/fimmu.2023.1279221","volume":"14","author":"G Xiao","year":"2023","unstructured":"Xiao G, Zhao Y, Wang X, Zeng C, Luo F, Jing J. Photothermally sensitive gold nanocage augments the antitumor efficiency of immune checkpoint blockade in immune \u201ccold\u201d tumors. Front Immunol. 2023;14:1279221.","journal-title":"Front Immunol"},{"key":"1316_CR342","doi-asserted-by":"publisher","first-page":"e2307193","DOI":"10.1002\/adma.202307193","volume":"35","author":"Z Wang","year":"2023","unstructured":"Wang Z, You T, Su Q, Deng W, Li J, Hu S, et al. Laser-activatable in situ vaccine enhances cancer-immunity cycle. Adv Mater. 2023;35:e2307193.","journal-title":"Adv Mater"},{"key":"1316_CR343","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09760-3","volume":"10","author":"W Yue","year":"2019","unstructured":"Yue W, Chen L, Yu L, Zhou B, Yin H, Ren W, et al. Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumor growth and metastases in mice. Nat Commun. 2019;10:2025.","journal-title":"Nat Commun"},{"key":"1316_CR344","doi-asserted-by":"crossref","unstructured":"Chen, J, Qiu M., Ye Z., Nyalile T., Li Y., Glass Z., et al., In situ cancer vaccination using lipidoid nanoparticles. Sci Adv. 2021. 7.","DOI":"10.1126\/sciadv.abf1244"},{"key":"1316_CR345","doi-asserted-by":"publisher","first-page":"e1386829","DOI":"10.1080\/2162402X.2017.1386829","volume":"6","author":"AD Garg","year":"2017","unstructured":"Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, et al. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology. 2017;6:e1386829.","journal-title":"Oncoimmunology"},{"key":"1316_CR346","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:160\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"1316_CR347","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","volume":"9","author":"R Fu","year":"2024","unstructured":"Fu R, Qi R, Xiong H, Lei X, Jiang Y, He J, et al. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Signal Transduct Target Ther. 2024;9:118.","journal-title":"Signal Transduct Target Ther"},{"key":"1316_CR348","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-024-00760-x","volume":"5","author":"X Chen","year":"2024","unstructured":"Chen X, Zhao J, Yue S, Li Z, Duan X, Lin Y, et al. An oncolytic virus delivering tumor-irrelevant bystander T-cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy. Nat Cancer. 2024;5:1063\u201381.","journal-title":"Nat Cancer"},{"key":"1316_CR349","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1126\/science.abk3436","volume":"374","author":"A Melcher","year":"2021","unstructured":"Melcher A, Harrington K, Vile R. Oncolytic virotherapy as immunotherapy. Science. 2021;374:1325\u20136.","journal-title":"Science"},{"key":"1316_CR350","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023;8:149.","journal-title":"Signal Transduct Target Ther"},{"key":"1316_CR351","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/1078-0432.CCR-23-3940","volume":"30","author":"AM D'alise","year":"2024","unstructured":"D'alise AM, Leoni G, Cotugno G, Siani L, Vitale R, Ruzza V, et al. Phase I trial of viral vector-based personalized vaccination elicits robust neoantigen-specific antitumor T-cell responses. Clin Cancer Res. 2024;30:2412\u201323.","journal-title":"Clin Cancer Res"},{"key":"1316_CR352","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1200\/JCO.2025.43.16_suppl.6016","volume":"43","author":"C Le Tourneau","year":"2025","unstructured":"Le Tourneau C, Delord JP, Lantz O, Dochy E, Ceppi M, Spring-Giusti C, et al. Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts). J Clin Oncol. 2025;43:6016\u20136016.","journal-title":"J Clin Oncol"},{"key":"1316_CR353","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-024-00908-9","volume":"21","author":"SY Kwon","year":"2024","unstructured":"Kwon SY, Thi-Thu Ngo H, Son J, Hong Y, Min JJ. Exploiting bacteria for cancer immunotherapy. Nat Rev Clin Oncol. 2024;21:569\u201389.","journal-title":"Nat Rev Clin Oncol"},{"key":"1316_CR354","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1126\/science.add9667","volume":"378","author":"CR Gurbatri","year":"2022","unstructured":"Gurbatri CR, Arpaia N, Danino T. Engineering bacteria as interactive cancer therapies. Science. 2022;378:858\u201364.","journal-title":"Science"},{"key":"1316_CR355","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39224-8","volume":"14","author":"DH Nguyen","year":"2023","unstructured":"Nguyen DH, Chong A, Hong Y, Min JJ. Bioengineering of bacteria for cancer immunotherapy. Nat Commun. 2023;14:3553.","journal-title":"Nat Commun"},{"key":"1316_CR356","doi-asserted-by":"publisher","first-page":"9038","DOI":"10.1200\/JCO.2022.40.16_suppl.9038","volume":"40","author":"GJ Gerstner","year":"2022","unstructured":"Gerstner GJ, Ramalingam SS, Lisberg AE, Farber CM, Morganstein N, Sanborn RE, et al. A phase 2 study of an off-the-shelf, multineoantigen vector (ADXS-503) in patients with metastatic non\u2013small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting. J Clin Oncol. 2022;40:9038\u20139038.","journal-title":"J Clin Oncol"},{"key":"1316_CR357","doi-asserted-by":"publisher","first-page":"CT007","DOI":"10.1158\/1538-7445.AM2019-CT007","volume":"79","author":"JR Hecht","year":"2019","unstructured":"Hecht JR, Goldman JW, Hayes S, Balli D, Princiotta MF, Dennie JG, et al. Abstract CT007: Safety and immunogenicity of a personalized neoantigen-Listeria vaccine in cancer patients. Cancer Res. 2019;79:CT007\u2013CT007.","journal-title":"Cancer Res"},{"key":"1316_CR358","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41586-024-08033-4","volume":"635","author":"A Redenti","year":"2024","unstructured":"Redenti A, Im J, Redenti B, Li F, Rouanne M, Sheng Z, et al. Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature. 2024;635:453\u201361.","journal-title":"Nature"},{"key":"1316_CR359","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief C, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360\u201378.","journal-title":"Nat Rev Cancer"},{"key":"1316_CR360","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-024-01091-9","volume":"25","author":"F Baharom","year":"2024","unstructured":"Baharom F, Hermans D, Delamarre L, Seder RA. Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumor microenvironment. Nat Rev Immunol. 2024;25:195\u2013211.","journal-title":"Nat Rev Immunol"},{"key":"1316_CR361","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ccell.2022.05.004","volume":"40","author":"K Kersten","year":"2022","unstructured":"Kersten K, Hu KH, Combes AJ, Samad B, Harwin T, Ray A, et al. Spatiotemporal codependency between macrophages and exhausted CD8(\u2009+\u2009) T cells in cancer. Cancer Cell. 2022;40:624\u2013638 e9.","journal-title":"Cancer Cell"},{"key":"1316_CR362","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","volume":"58","author":"J Waibl Polania","year":"2025","unstructured":"Waibl Polania J, Hoyt-Miggelbrink A, Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, et al. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity. 2025;58:232\u2013246.e6.","journal-title":"Immunity"},{"key":"1316_CR363","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41416-023-02474-w","volume":"130","author":"JH Jo","year":"2024","unstructured":"Jo JH, Kim YT, Choi HS, Kim HG, Lee HS, Choi YW, et al. Efficacy of GV1001 with gemcitabine\/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4\/2015): an open-label, randomized, phase 3 trial. Br J Cancer. 2024;130:43\u201352.","journal-title":"Br J Cancer"},{"key":"1316_CR364","doi-asserted-by":"publisher","first-page":"577","DOI":"10.7150\/jca.7028","volume":"4","author":"NK Ibrahim","year":"2013","unstructured":"Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, et al. Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial. J Cancer. 2013;4:577\u201384.","journal-title":"J Cancer"},{"key":"1316_CR365","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomized, double-blind, international phase 3 trial. Lancet Oncol. 2017;18:1373\u201385.","journal-title":"Lancet Oncol"},{"key":"1316_CR366","doi-asserted-by":"publisher","first-page":"LBA4004","DOI":"10.1200\/jco.2013.31.18_suppl.lba4004","volume":"31","author":"GW Middleton","year":"2013","unstructured":"Middleton GW, Valle JW, Wadsley J, Propper D, Coxon FY, Ross PJ, et al. A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer. J Clin Oncol. 2013;31:LBA4004\u2013LBA4004.","journal-title":"J Clin Oncol"},{"key":"1316_CR367","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10388-024-01072-w","volume":"21","author":"T Makino","year":"2024","unstructured":"Makino T, Miyata H, Yasuda T, Kitagawa Y, Muro K, Park JH, et al. A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma. Esophagus. 2024;21:447\u201355.","journal-title":"Esophagus"},{"key":"1316_CR368","doi-asserted-by":"publisher","first-page":"TPS617","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS617","volume":"41","author":"S Patel","year":"2023","unstructured":"Patel S, Thompson J, Patel M, Daugherty FJ, Rimawi MF. Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2\u2009+\u2009GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neoadjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01. J Clin Oncol. 2023;41:TPS617\u2013TPS617.","journal-title":"J Clin Oncol"},{"key":"1316_CR369","doi-asserted-by":"crossref","unstructured":"Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, et al. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Sci Transl Med. 2020;12:eaaz8235.","DOI":"10.1126\/scitranslmed.aaz8235"},{"key":"1316_CR370","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-15-2594","volume":"22","author":"MI van Poelgeest","year":"2016","unstructured":"van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM, Berends-van der Meer DM, et al. Vaccination against oncoproteins of HPV16 for noninvasive vulvar\/vaginal lesions: lesion clearance is related to the strength of the T-cell response. Clin Cancer Res. 2016;22:2342\u201350.","journal-title":"Clin Cancer Res"},{"key":"1316_CR371","doi-asserted-by":"crossref","unstructured":"Speetjens FM, Welters MJP, Slingerland M, van Poelgeest MIE, de Vos van Steenwijk PJ, Roozen I, et al. Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions. J Immunother Cancer. 2022;10:e005016.","DOI":"10.1136\/jitc-2022-005016"},{"key":"1316_CR372","doi-asserted-by":"publisher","first-page":"TPS2700","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2700","volume":"42","author":"Y Lou","year":"2024","unstructured":"Lou Y, Chumsri S, Asmann YW, Shi Q, Reynolds J, Necela B, et al. A phase I pilot study of personalized neoantigen peptide-based vaccine in combination with pembrolizumab in advanced solid tumors (PNeoVCA). J Clin Oncol. 2024;42:TPS2700\u2013TPS2700.","journal-title":"J Clin Oncol"},{"key":"1316_CR373","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1200\/JCO.2021.39.15_suppl.2613","volume":"39","author":"ML Gillison","year":"2021","unstructured":"Gillison ML, Awad MM, Twardowski P, Sukari A, Johnson ML, Stein MN, et al. Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors. J Clin Oncol. 2021;39:2613\u20132613.","journal-title":"J Clin Oncol"},{"key":"1316_CR374","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.annonc.2024.05.040","volume":"35","author":"ME Elez Fernandez","year":"2024","unstructured":"Elez Fernandez ME, Maurel J, Morris V, Kopetz S, Galligan B, Ali S, et al. 29\u2009P Characterization of T-cell responses induced by the individualized mRNA neoantigen vaccine autogene cevumeran in adjuvant stage II (high risk)\/stage III colorectal cancer (CRC) patients (pts) from the biomarker cohort of the phase II BNT122-01 trial. Ann Oncol. 2024;35:S14\u2013S15.","journal-title":"Ann Oncol"},{"key":"1316_CR375","doi-asserted-by":"publisher","first-page":"S627","DOI":"10.1016\/j.annonc.2024.08.938","volume":"35","author":"NF Saba","year":"2024","unstructured":"Saba NF, Klinghammer K, Castelluci E, Colevas AD, Rutkowski T, Thurner D, et al. 877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16\u2009+\u2009HNSCC. Ann Oncol. 2024;35:S627.","journal-title":"Ann Oncol"},{"key":"1316_CR376","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1016\/j.annonc.2024.08.729","volume":"35","author":"MA Khattak","year":"2024","unstructured":"Khattak MA, Sullivan RJ, Gutierrez M, Jimeno A, Thomas SS, Long GV, et al. 663P First-in-human, phase I\/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1\/IDO1 antigen-specific therapy, in advanced\/refractory solid tumors. Ann Oncol. 2024;35:S521\u2013S522.","journal-title":"Ann Oncol"},{"key":"1316_CR377","doi-asserted-by":"publisher","first-page":"S406","DOI":"10.1016\/j.annonc.2024.08.510","volume":"35","author":"G Tabatabai","year":"2024","unstructured":"Tabatabai G, Freres P, Glas M, Hau P, von Baumgarten L, van den Bent MJ, et al. 44\u00b0First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): First results from the dose escalation phase. Ann Oncol. 2024;35:S406.","journal-title":"Ann Oncol"},{"key":"1316_CR378","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1200\/JCO.2019.37.15_suppl.2641","volume":"37","author":"AM Arance Fernandez","year":"2019","unstructured":"Arance Fernandez AM, Baurain JF, Vulsteke C, Rutten A, Soria A, Carrasco J, et al. A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: analysis of safety and immunogenicity. J Clin Oncol. 2019;37:2641\u20132641.","journal-title":"J Clin Oncol"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01316-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01316-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01316-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:34:00Z","timestamp":1757223240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-025-01316-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":378,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1316"],"URL":"https:\/\/doi.org\/10.1038\/s41423-025-01316-4","relation":{},"ISSN":["2042-0226"],"issn-type":[{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest. Dr. Yang-Xin Fu is an editorial board member of Cellular & Molecular Immunology, but he has not been involved in peer review or decision-making related to the article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}